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To my children with love
The beginning of all science is wondering why
things are the way they are.
All vetenskaps början är förvåningen över att
tingen är som de är.
— Aristotle
vbackground: Alzheimer’s disease (AD) is a severe neurodegenerative disease that mainly afflicts elderly 
persons, with a characteristic progressive decline of cognitive functions and dementia. It is believed that 
the majority of all AD patients are affected by the sporadic form, thus caused by the combined effects 
of several risk factors, such as elevated cholesterol levels in midlife and deficiencies in the lipoprotein 
transporters apolipoprotein E (ApoE). Cholesterol play an essential role in the central nervous system 
(CNS) were it maintain normal physiological conditions, and is a requirement for the ability of neurons 
to communicate. It has previously been demonstrated that the cholesterol homeostasis in the CNS is 
maintained by a slow conversion of brain cholesterol into 24(S)-hydroxycholesterol, with a net flux of 
27-hydroxycholesterol from the circulation into the brain. The importance of a preserved cholesterol 
homeostasis has been supported by the observation that dietary cholesterol may induce an inflammation 
in the CNS, and increase the levels of pro-inflammatory mediators. It has, in direct association with these 
observations, been demonstrated that plasma levels of pro-inflammatory proteins, such as interleukin-6, 
are increased before the clinical onset of AD, after which a chronic state of inflammation often is found. 
Accordingly, it has been suggested that memory and cognitive functions could benefit from a cholesterol-
lowering therapy. studies: The research presented in this thesis has examined the effect of cholesterol and 
cholesterol-lowering therapy with rosuvastatin, on key factors associated with AD. The experimental setup 
consisted of in vitro-models with human neuroblastoma SH-SY5Y cells (paper I–II), and in vivo-models 
with wild type (WT) and ApoE knockout (ApoE-/-) mice, provided with high levels of dietary cholesterol 
for 18 weeks (paper III–IV). The hydrophilic compound rosuvastatin is an effective inhibitor of choles-
terol synthesis and has been demonstrated to be an effective treatment for hypercholesterolemia, with an 
indirect effect on microglial activation and inflammation through isoprenoid depletion. results: Paper 
I describes the selective non-amyloidogenic processing (α-secretase activity) of the amyloid precursor 
protein (APP), induced by 24(S)-hydroxycholesterol, with a subsequent increased ratio of α-/β-secretase 
activity, and increased levels of soluble APPα and total soluble sAPP; effects significantly decreased by 
the presence of 27-hydroxycholesterol. Paper II describes the effect of pre-treating in vitro-cultures with 
rosuvastatin prior exposure to Aβ oligomers. The treatment was found to decrease caspase-3 activity and 
promote cell survival, with a selective non-amyloidogenic processing of APP. However, no influence was 
observed on cell viability, with a potential explanation in a downregulated metabolism. Paper III–IV de-
scribes the effect of high levels of dietary cholesterol in vivo, with increased microglial activation in WT 
mice, increased gliosis in ApoE-/- mice and subsequent increased plasma IL-6 levels in WT and ApoE-/- 
mice. The elevated levels of total cholesterol (TC) were found to be caused by increased levels of HDL and 
LDL in WT mice, whereas only LDL where increased in ApoE-/- mice. Plasma TC levels were correlated 
with body weight gain in WT and ApoE-/- mice. Furthermore, the selective and ApoE-associated influ-
ence induced by the rosuvastatin therapy, on the effects of dietary cholesterol, is described. We observed a 
decreased microglial activation and gliosis in WT and ApoE-/- mice, with plasma IL-6 levels decreased by 
45% in WT mice, without reaching significance. The elevated levels of TC and LDL were decreased in WT 
mice, whereas no effect was observed on the levels of TC, HDL or LDL in ApoE-/- mice. Body weight gain 
was decreased in WT mice, with a previously unpublished age- and ApoE-associated declining response 
to the therapy observed in ApoE-/- mice. summary: The presented thesis has examined the connection 
between Alzheimer’s disease and cholesterol, and demonstrated a selection of detrimental effects which 
may be induced by high levels of dietary cholesterol. Furthermore, the thesis has demonstrated the poten-
tial for a cholesterol-lowering therapy with rosuvastatin to exercise a preventive influence, with an age- 
and ApoE-associated response. The latter is an important observation, which indicates that rosuvastatin 
may be an effective therapy up to a certain point in the progression of the disease, after which the effects 
decline. In conclusion, the results discussed in this thesis offer a hypothetical explanation, at least in part, 
for the discrepancies observed in clinical trials on statins. In addition, this thesis have been able to support 
the theoretical connection between AD and plasma cholesterol levels with the observation that 27-hy-
droxycholesterol may exhibit an inhibitory influence on 24(S)-hydroxycholesterol and non-AD processes. 
It is suggested that persons with high risk of developing AD may benefit from a rosuvastatin therapy, in 
combination with lifestyle precautions taken in early midlife. The approach could be an effective lifestyle-
preventive strategy, with preserved cognitive functions and quality of life at high age.
keywords: Alzheimer’s disease, dietary cholesterol, rosuvastatin, apolipoprotein E, α-secretase, β-secre-
tase, α-/β-secretase ratio, soluble APPα, gliosis, microglial load, interleukin-6, caspase-3, body weight gain, 
lifestyle-preventive strategy, 24(S)-hydroxycholesterol, 27-hydroxycholesterol
Abstract
vi
Sammanfattning
bakgrund: Alzheimers sjukdom (AD) är en allvarlig neurodegenerativ sjukdom som framförallt drabbar 
personer i hög ålder, med en karakteristisk progressiv försämring av kognitiva funktioner och demens. Med un-
dantag för vissa riskfaktorer har man inte funnit någon direkt ärftlig koppling till sporadisk AD som är den van-
ligaste formen av AD. Istället anser man att den främsta bakomliggande orsaken är den kombinerade effekten 
av flera olika riskfaktorer; en kombinerad risk där yttre och inre faktorer tillsammans är av avgörande betydelse. 
Två av dessa riskfaktorer är ökade kolesterolnivåer i medelåldern, och en medfödd brist i lipoproteintranspor-
tören apolipoprotein E (ApoE), där isoform ApoE ε4 har visat sig vara en av de viktigaste indikationerna för 
sporadisk AD. Kolesterol har en essentiell roll i det centrala nervsystemet (CNS), där det under normala förhål-
landen hjälper till att underhålla de fysiologiska funktionerna och är nödvändigt för att nervcellerna ska kunna 
kommunicera. Tidigare studier har visat att kolesterolnivåerna i CNS kontrolleras av en långsam omvandling 
av kolesterol till 24(S)-hydroxykolesterol, med ett netto flux av 27-hydroxykolesterol i motsatt riktning, från 
cirkulationen in i hjärnan. Betydelsen av en bevarad kolesterolhomeostas har förstärkts av observationerna 
att en kolesterolrik diet kan framkalla en inflammation i CNS, och orsaka en förhöjning av inflammatoriska 
agenter. I direkt association till denna iakttagelse har man även observerat att plasmanivåerna av inflammato-
riska cytokiner, däribland interleukin-6 (IL-6), ökar före den kliniska definitionen av AD, vid vilken man ofta 
finner en kronisk inflammation i hjärnan. Följaktligen har det föreslagits att minne och kognitiva funktioner 
skulle gynnas av kolesterolsänkande terapier. studier: Den forskning som den här avhandlingen bygger på 
har undersökt hur kolesterol och kolesterolsänkande terapier med rosuvastatin påverkar olika nyckelfaktorer 
associerade med AD. Det experimentella upplägget bestod av in vitro-modeller med humana neuroblastoma 
SH-SY5Y celler (artikel I–II), och in vivo-modeller med kontrollmöss av ’vildtyp’ (WT), samt möss med en 
’knockout’-mutation av ApoE (ApoE-/-) (artikel III–IV). Det hydrofila substansen rosuvastatin är en effektiv 
hämmare av kolesterolsyntesen och har visat sig vara en effektiv behandling mot förhöjda kolesterolnivåer, med 
indirekta effekter på inflammationer genom en uttömning av isoprenoiderna. resultat: Artikel I beskriver 
hur 24(S)-hydroxykolesterol selektivt inducerar den icke-amyloidogena bearbetningen (α-secretase aktivitet) av 
amyloid prekursor protein (APP), med ett ökat ratio mellan α-/β-secretase aktivitet och ökande nivåer av lösligt 
APPα och totalt lösligt sAPP; effekter som tydligt förminskades i närvaro av 27-hydroxykolesterol. Artikel II 
beskriver effekterna av att förbehandla in vitro-kulturer med rosuvastatin, före exponering av Aβ oligomerer. 
Behandlingen ledde till en minskning av caspase-3 aktivitet och främjade cellöverlevnaden, med en selektiv in-
ducering av den icke-amyloidogena bearbetningen av APP. Cellernas viabilitet påverkades emellertid inte, vilket 
eventuellt kan förklaras av en nedreglerad metabolism. Artikel III–IV beskriver effekterna av en kolesterolrik 
diet in vivo, med en ökad aktivering av mikrogliaceller i WT möss, ökad gliosis i ApoE-/- möss och ökade plasma 
IL-6 nivåer i både WT och ApoE-/- möss. De ökade nivåerna av totat kolesterol (TC) i WT möss var relaterat 
med ökade nivåer av HDL och LDL, medan TC nivåerna i ApoE-/- möss endast var relaterat med ökade nivåer 
av LDL. De ökade TC nivåerna var emellertid korrelerade med den relativa ökningen av kroppsvikt i både WT 
och ApoE-/- möss. Här beskrivs även den selektiva och ApoE-associerade inverkan som rosuvastatin utövade 
på effekterna av den kolesterolrika dieten. Vi observerade en minskad aktivering av mikrogliaceller och gliosis 
i WT och ApoE-/- möss, med en 45% sänkning av plasma IL-6 nivåerna i WT möss, utan att nå signifikans. De 
förhöjda nivåerna av TC och LDL i WT möss sänktes av behandlingen med rosuvastatin, parallellt med ett svagt 
svar på behandlingen i ApoE-/- möss och oförändrade nivåer av TC, HDL och LDL. Den relativa ökningen av 
kroppsvikt i WT möss påverkades av behandlingen, med en tidigare opublicerad ålders- och ApoE-associerad 
minskad respons på behandlingen i ApoE-/- möss. summering: Den presenterade avhandlingen har undersökt 
kopplingen mellan Alzheimers sjukdom och kolesterol, med en demonstration av ett urval skaldiga effekter som 
kan framkallas av en kolesterolrik diet. Vi har även presenterat de förebyggande effekter som kan induceras av en 
kolesterolsänkande behandling med rosuvastatin, och de rön som tyder på att behandlingen är associerad med 
ålder och ApoE. Detta är en viktig observation som indikerar att rosuvastatin är en effektiv behandling fram till 
ett visst steg i sjukdomsprocessen, efter vilket effekterna avtar. Denna avhandling erbjuder därmed en hypotetisk 
förklaring till en del avvikelser som har observerats i kliniska studier på statiner. Nya rön har också presenterats 
som stödjer koppling mellan AD och plasmakolesterolnivåer, där 27-hydroxykolsterol har befunnits utöva ett 
hämmande inflytande på 24(S)-hydroxykolesterol och icke-AD processer. Vi föreslår att personer med hög risk 
att utveckla AD skulle kunna gagnas av en rosuvastatin terapi, i kombination med förebyggande åtgärder i livs-
stil från och med tidig medelålder. Metoden skulle kunna vara en effektiv livsstilsförebyggande strategi för att 
bevara kognitiva funktioner och livskvalitet i hög ålder.
nyckelord: Alzheimers sjukdom, kolesterolrik diet, rosuvastatin, apolipoprotein E, α-secretase, β-secretase, 
α-/β-secretase aktivitets ratio, lösligt APPα, gliosis, microglia celler, interleukin-6, caspase-3, relativ ökning av 
kroppsvikt, livsstilsförebyggande strategi, 24(S)-hydroxykolesterol, 27-hydroxykolesterol
Se även Populärvetenskaplig översikt.
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24S-OHC . . . . . . . . . . . 24(S)-hydroxycholesterol
27-OHC . . . . . . . . . . . . 27-hydroxycholesterol
Aβ . . . . . . . . . . . . . . . . . amyloid-β
ABComplex/HRP . . . . avidin-biotin horseradish peroxidase complex
AD  . . . . . . . . . . . . . . . . Alzheimer’s disease
ADAM . . . . . . . . . . . . . a disintegrin and metalloprotease
AICD . . . . . . . . . . . . . . APP intracellular domain
APP . . . . . . . . . . . . . . . . amyloid precursor protein
ApoE . . . . . . . . . . . . . . . apolipoprotein E
ApoE-/-  . . . . . . . . . . . . apolipoprotein E knock-out
BACE  . . . . . . . . . . . . . . β-site amyloid precursor protein-cleaving enzyme
BBB . . . . . . . . . . . . . . . . blood-brain barrier
BSA . . . . . . . . . . . . . . . . bovine serum albumin fraction V
CTFα; CTFβ  . . . . . . . . membrane-bound C-terminal fragment of 83 or 99 residues
CNS  . . . . . . . . . . . . . . . central nervous system
CR . . . . . . . . . . . . . . . . . caloric restriction
CSF . . . . . . . . . . . . . . . . cerebrospinal fluid
CYP46A1; CYP46a1  . cholesterol 24-hydroxylase of human or murine origin
DAB . . . . . . . . . . . . . . . diaminobenzidine
DMEM:F12 . . . . . . . . . Dulbecco’s Modified Eagle’s Medium:Ham’s F12
F4/80  . . . . . . . . . . . . . . microglia cell marker
FAD  . . . . . . . . . . . . . . . hereditary (familial) AD
FBS . . . . . . . . . . . . . . . . fetal bovine serum
GFAP . . . . . . . . . . . . . . glial fibrillary acidic protein
HC  . . . . . . . . . . . . . . . . western type-high cholesterol (diet)
HCRS . . . . . . . . . . . . . . western type-high cholesterol (diet) and rosuvastatin (therapy)
HDL . . . . . . . . . . . . . . . high density lipoproteins
HMG-CoA  . . . . . . . . . 3-hydroxy-3-methylglutaryl-Coenzyme A
IL-6 . . . . . . . . . . . . . . . . interleukin 6
LDL . . . . . . . . . . . . . . . . low density lipoproteins
NMDA  . . . . . . . . . . . . N-methylD-aspartate
MCI  . . . . . . . . . . . . . . . mild cognitive impairment
NFE  . . . . . . . . . . . . . . . nitrogen-free extract
NPC . . . . . . . . . . . . . . . Niemann-Pick Type C disease
NSAIDs . . . . . . . . . . . . non-steroidal anti-inflammatory drugs
NTFs . . . . . . . . . . . . . . . neurofibrillary tangles
P3 . . . . . . . . . . . . . . . . . short peptide fragment
PBS . . . . . . . . . . . . . . . . phosphate buffered saline
PHFs . . . . . . . . . . . . . . . paired helical filaments
PI . . . . . . . . . . . . . . . . . . propidium iodide
RS . . . . . . . . . . . . . . . . . rosuvastatin (therapy)
PS1; PS2 . . . . . . . . . . . . presenilin-1 or presenilin-2; presenilins
RT . . . . . . . . . . . . . . . . . room temperature
SAD  . . . . . . . . . . . . . . . sporadic (non-familial) AD
sAPPα; sAPPβ . . . . . . . soluble fragments of APP, cleaved at  
the α- or β-secretase cleavage site
TACE . . . . . . . . . . . . . . tumour necrosis factor-α converting enzyme
TC . . . . . . . . . . . . . . . . . total cholesterol
WT . . . . . . . . . . . . . . . . wild-type
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1Introduction
alzheimer’s disease
General background
In 1906, the German psychiatrist Alois Alzheimer (1864–1915) presented the 
case history of a middle-aged demented woman named Auguste D. The diag-
nosis described ‘a peculiar, severe disease process of the cerebral cortex’, which 
eventually would be known as Alzheimer’s disease (AD) [Alzheimer, 1907]. 
Since this initial discovery, AD has become recognized as one of the most 
important diseases amongst the elderly. It is a complex disorder, characterized 
by a major neurodegeneration causing a progressive cognitive decline and de-
mentia. Although research on dementia and neurodegeneration has developed 
a number of symptomatic anti-dementia drugs to ease the burden, we are still 
far from finding a cure. 
The worldwide population of demented persons was estimated to approxi-
mately 30 million people in 2003 [Wimo et al., 2006], with an estimated preva-
lence exceeding 10% in people over the age of 65 years [Evans et al., 1989]. 
Interestingly, demographic studies have revealed that prevalence is associated 
with age; below 5% between the age of 65 and 74 years, compared with almost 
50% among those over the age of 85 years [Evans et al., 1989].  We still have to 
discover what effects the general awareness about health and life style will have 
on prevalence of AD, but the median age is increasing world-wide, and provid-
ing care for the increasing number of demented patients is going to present an 
enormous challenge; it has been estimated that the number of demented per-
sons in Europe will increase by at least 45% between the years 2000 and 2050, 
assuming that mortality remains constant [Wancata et al., 2003].
Dementia (from Latin [de-] apart, away and [mens] mind) is, in its clinical 
definition, the progressive decline of cognitive function, due to damage or dis-
ease of the brain, beyond what might be expected from normal aging. Demen-
tia is a non-specific term encompassing many disease processes, in the same 
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way that many neuropathological hallmarks in AD per se, not are AD-specific 
events. Closely related with AD is the condition mild cognitive impairment 
(MCI), a diagnosis believed to affect up to a third of the people over the age of 
65 years. Whilst first considered a separate syndrome, it is now recognized as a 
frequent prelude to AD – a transitional phase from which 20–50% will develop 
full AD within 3 years [Kluger et al., 1999; Schmidtke et al., 2007]. 
As a consequence of the disease process it is commonly assumed that 
patients with dementia and severe cognitive disabilities are no longer “re-
ally there”, with their selfhood open to question despite the persistence of an 
animate body. Patients with severe AD require such amounts of informal care 
from their care givers, and inflict such a deep psychological effect on their 
families, that what we have is a situation that could be described in terms of 
burden, stress and depression [Jonsson, 2003; Wimo, 2004]. Thus, we have a 
situation where care givers and families may suffer more from the disease than 
the patients. In order to accurately estimate the growing cost of dementia care 
for the society, we need to consider the quality of life for patients, care givers 
and families alike.
Classification of Alzheimer’s disease
AD can be classified into hereditary (familial) AD (FAD) or sporadic (non-fa-
milial) AD (SAD), depending on the age of onset and underlying cause of the 
disease. However, they have nearly identical clinical symptoms, with similar 
neuropathological hallmarks, and are regarded as the same disease in clinical 
treatment and research.
FAD is a hereditary disease, comprising 10–15% of the diagnosed AD pa-
tients, with a disease onset in early midlife; sometimes with symptoms becom-
ing evident as early as age 28 [Vetrivel and Thinakaran, 2006]. A genetic causal 
link can be found in a small percentage of the patients, with mutations in three 
particular genes associated with FAD: the amyloid precursor protein (APP), 
presenilin-1 (PS1), and presenilin-2 (PS2). Among these three the majority 
have been found in the presenilins, with more than 160 established mutations 
in PS1, causing the most aggressive forms of FAD [Vetrivel and Thinakaran, 
2006; Goedert and Spillantini, 2006]. 
SAD has a symptomatic onset after age 65 and comprises the remaining 
85–90% suffering from AD. The only known genetic linkage with SAD is an 
isoform of apolipoprotein E [Goedert and Spillantini, 2006], although a num-
ber of risk factors have been identified that may increase the likelihood of 
developing the disease.
Common risk factors
AD is in the majority of cases caused by the effects of several and often separate 
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factors which interacts and affects the brain. It is believed that when the com-
bined influence of these, so called, environmental and biological risk factors, 
cross a yet undefined threshold level, they overwhelm the natural self-repair 
mechanisms in the brain, thus causing the disease. Most prominent of these 
risk factors are: high age; family history; apolipoprotein E ε4 (ApoE ε4); mild 
cognitive impairment (MCI); midlife elevated cholesterol level; chronic in-
flammatory conditions; obesity; head injuries; low levels of formal education; 
diabetes; Down’s syndrome; clinical depression; stroke; high blood pressure; 
stress and inadequate exercising of the brain [Kivipelto et al., 2001; Turner, 
2006; Ni et al., 2006]. Many of these are further included in the metabolic syn-
drome. Risk factors that are less firmly associated with AD include smoking, 
excessive alcohol consumption and narcotic drugs. 
Epidemiological studies have reported a higher prevalence and incidence of 
SAD in women, but the biochemical basis for this gender-disparate susceptibil-
ity is still largely unknown. Some risk factors that deserve further explanation 
and not will be discussed in greater detail elsewhere are:
Family history
AD occurs in most cases regardless of family history. A significantly higher risk 
is only conceivable if the family history contains two generations or more of 
first degree relatives (i.e. grandparents and parents, or parents and siblings on 
the same side of the family), with diagnosed AD (and not any other form of 
dementia) and if the age of onset was before 65 years of age in both cases.
Down’s syndrome
Down’s syndrome is caused by a trisomy of chromosome 21, the same chromo-
some that contains the APP gene. The number of people with Down’s syndrome 
that survive to middle age and develop AD is high, as expected, but the disease 
is not inevitable [Turner, 2006; Margallo-Lana et al, 2007], which emphasizes 
the importance of further risk factors.
Metabolic syndrome
The metabolic syndrome is a syndrome characterized by abnormalities in insu-
lin, glucose, and lipoprotein metabolism, as well as hypertension and obesity. It 
is an acknowledged risk factor for cardiovascular diseases and has been signifi-
cantly associated with AD [Vanhanen et al., 2006; Razay et al., 2007]. 
In a comparison study of patients with and without the metabolic syn-
drome, it was revealed that AD was more frequently found in patients with 
the syndrome. An interesting and unexpected finding was the occurrence of 
a gender-specific difference. The prevalence of AD was found to be higher in 
women with the metabolic syndrome, whilst no difference was found in men 
[Vanhanen et al., 2006]. The association between the metabolic syndrome and 
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AD, as well as the gender specific risk association, is of high significance, given 
that it might be possible to target by relatively simple lifestyle interventions 
[Scott, 2003].
Mild cognitive impairment
Individuals with MCI are regularly able to function quite normally, with few 
complaints about their cognitive capacity, regardless of the fact that a major 
neurodegeneration has often occurred [Tronsco et al., 1998; Morris et al., 2001]. 
Individuals with MCI is neither normal nor demented; there is evidence of 
cognitive deterioration; and activities of daily life are preserved, with complex 
instrumental functions either intact or minimally impaired [Winblad et al., 
2004]. Researchers are investigating the use of neuropsychological assessment, 
peripheral and CSF biomarkers, as well as structural and functional MRI (mag-
net resonance imagining) to distinguish MCI from normal age-related memory 
changes, and identify subjects with pre-clinical AD [Zetterberg et al., 2003; 
Korf et al., 2004]. For example, recent studies have found that the Aβ1-42/1-40 
ratio may become a useful biomarker for identifying cognitively normal aging 
subjects who are at increased risk for developing MCI or AD [Graff-Radford et 
al., 2007]. But MCI is not necessarily AD. Instead, a MCI diagnosis may serve 
as a valuable early warning signal for many treatable symptoms such as stress, 
depression, heart disease, hearing loss, nutritional deficiencies and inactivity.
Clinical symptoms and diagnosis
Language and memory are recognized as two of the major building blocks 
in the construction of selfhood, and any disorder that impairs these abilities 
is considered to be both frightful and devastating. The clinical case notes on 
Auguste D. reveal some classic symptoms; the agitated suspicion she felt to-
wards her husband; her increasing loss of memory and interests; her inability 
to interact socially; and her increasingly abnormal and disruptive behaviours 
[Alzheimer, 1907]. 
In order to set a definitive diagnosis we need to fulfil certain neuropatho-
logical criteria such as the presence of neuritic plaques and/or NFTs [Tierney 
et al., 1988; Khachaturian, 1985; Mirra et al., 1991]. These major anatomical 
changes in the brain were accurately described by Dr. Alzheimer [Graeber et 
al., 1998; Graeber, 1999], but occur in a number of different neurological dis-
orders and are not AD-specific events as such. Accordingly, the criteria must be 
fulfilled but are by themselves not sufficient to set an accurate diagnosis; they 
need to be supported by clinical symptoms and a clinical diagnosis to rule out 
other types of dementias and neurodegenerative disorders.
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Symptoms and general progression
The general progression of the disease can be outlined in three progressive 
stages, stretching over a period of 3–10 years depending on the age at onset 
[Brookmeyer et al., 2002; Bonsignore and Heun, 2003]. However, this is only a 
general progression and AD is affecting all patients differently.
(i) Early stage in the disease progression (mild AD); symptoms may not 
yet be noticeable. The patients tend to have less energy and spontaneity. 
They exhibit minor memory loss, personality changes and mood swings, 
and are slow to learn and react. After a while they start to shy away from 
anything new and prefer the familiar. Memory loss begins to affect job 
performance. The patients are confused, get lost easily, and demonstrate 
poor judgment. 
(ii) Middle stage; the patient can still perform tasks independently, but may 
need assistance with more complicated activities. Speech and under-
standing become slower, and patients often lose their train of thought 
in mid-sentence. They may also get lost while travelling or forget to pay 
bills. As the patients become aware of this loss of control, they may be-
come depressed, irritable and restless. The individual is clearly becoming 
disabled. The distant past may be recalled, while more recent events are 
difficult to remember. The progressing disease affects the patients’ abil-
ity to understand where they are, the date and the time. Caregivers and 
family must give clear instructions and repeat them often. As the mind 
continues to slip away, the patients may invent words and not recognize 
familiar faces.
(iii) Late stage (severe AD); the patients lose their ability to chew and swal-
low. Their very self-hood seems to be vanishing. Memory is often very 
poor and the patients can no longer recognize anyone. They lose bowel 
and bladder control, and will eventually need constant care. They become 
vulnerable to pneumonia, infection and other diseases. Respiratory prob-
lems get worse, especially when the patients become confined to bed, and 
eventually, death is inevitable.
Neuropathological hallmarks and diagnosis
The neuropathological changes found in the AD brain include shrinkage of 
gyri, widening of sulci and enlargements of the ventricles. Brain regions most 
affected are the enthorinal cortex, hippocampus, amygdala, neocortex and 
some basal forebrain nuclei [Braak and Braak, 1994; Gosche et al., 2002], but 
neurodegeneration will soon occur in other regions, including the temporal 
and parietal lobes, and in some cases also the frontal and occipital lobes [Braak 
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and Braak, 1994]. Of particular concern for the classic symptoms occurring in 
AD, are the neuropathological changes in the hippocampus, important as they 
affect the area of the brain involved in learning and memory tasks.
Histopathological examinations reveal a widespread neuronal degeneration, 
loss of synapses, intracellular neurofibrillary tangles (NFTs; Figure 1A) and 
neuritic plaques with clusters of activated microglial cells and macrophages 
(Figure 1B) [Alzheimer, 1907; Tarkowski et al., 2003]. Considering the strong 
correlation between synaptic loss and dementia, it has been suggested that AD 
could be regarded as a disease of synaptic failure [Sorrentino and Bonavita, 
2007]. 
Neurodegeneration in Alzheimer’s disease  
The neuronal death found in the AD brain is believed to be executed primarily 
by apoptosis, which is a highly regulated physiological event [Tarkowski, 2003] 
and, to a lesser degree, necrosis, which is a passive pathological event arising 
from insult or trauma. However, it appears that these processes may have an 
overlap in neuronal death, as Aβ peptides have been suggested to induce a 
Figure 1A. Hallmark of AD; intracellular neurofibrillary tangle composed of 
hyperphosphorylated tau, aggregated into paired helical filaments (Bielschowsky 
silver staining), by courtesy of Associate professor Nenad Bogdanovic.
Figure 1B. Hallmark of AD; extracellu-
lar mature (“classic”) plaque composed of 
a dense central core of Aβ (Bielschowsky 
silver staining), by courtesy of Associate 
professor Nenad Bogdanovic.
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rapid response in neurons, representing necrosis, followed by a long term 
apoptosis [Ankarcrona et al., 1995]. Several hypotheses have been suggested to 
explain the selectivity of the neurodegeneration, including the possibility that 
Aβ peptides could function as an extracellular signal molecule for caspase-3 
activation [Takuma et al., 2004]. 
The activation of caspase-3 represents an early physiological marker for 
apoptosis and determines the apoptotic pathway [Janicke et al., 1998; Slee et al., 
1999; Nicotera et al., 1999; Riedl and Shi, 2004], with characteristic cleavages of 
vital cellular substrates, apoptotic morphology and internucleosomal fragmen-
tation of DNA. Typical morphological features are shrinkage of the cell body, 
fragmentation into membrane-bound apoptotic bodies and rapid phagocytosis 
by neighbouring cells [Saraste and Pulkki, 2000]. 
Neuritic plaques
Any single neuritic (amyloid) plaque in AD may contain dystrophic neuritis 
of varying neurotransmitter specificities, reflecting the normal distribution 
of cell bodies and axons [Struble et al., 1987]. Even though the pyramidal 
glutamatergic hippocampal neurons seem to be especially vulnerable, and are 
affected early in the pathological process [Beach et al., 1982], it is believed that 
the progressive accumulation of neuritic plaques and synaptic failure involve 
local fibres of intrinsic and projection neurons in a non-specific fashion [Sel-
koe, 1991].
 The classic neuritic plaque in AD is a complex lesion of the cortical neu-
ropil containing several abnormal features; a central deposit of extracellular 
amyloid-β (Aβ) fibrils, surrounded by dystrophic neuritis, activated microg-
lial cells and astrocytes in a manner that reminisces of glial scarring [Selkoe, 
1991]. However, all plaques are not identical. They change their morphology 
during development, which allows us to distinguish between plaques at differ-
ent stages: 
• Diffuse (early) plaques have a loose accumulation of Aβ and no surround-
ing dystrophic neuritis. 
• Immature (primitive) plaques have a loose accumulation of Aβ and are sur-
rounded by dystrophic neuritis. 
• Mature (classic) plaques consists of a dense central core of Aβ, surrounded 
by a halo measuring about 0.2 millimetres in diameter, activated glial cells 
and a ring of dystrophic neuritis associated with wisps of Aβ. 
• Hypermature (burned out) plaques with a dense core of Aβ surrounded by 
reactive astrocytes and no dystrophic neuritis.  
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Interestingly, inflammatory mediators produced by activated glial cells, are 
more likely to occur in the early diffuse plaques without neuritic pathology, 
rather than in the late stage burned-out plaques, which is consistent with their 
alleged lesion-promoting role [Bauer et al., 1991; Gruol and Nelson, 1997; Fass-
bender et al., 2000].
Amyloid-β peptide
The occurrence of Aβ peptides in neuritic plaques is, as previously described, 
one of several criteria needed for an accurate diagnosis of AD Figure 1B. It is 
also undisputable that many of the known mutations in AD are affecting APP 
processing and the production of Aβ. However, the total Aβ load does not nec-
essarily predict the degree of dementia, as large deposits of Aβ peptides can be 
found also in cognitively intact brains [Webster et al., 1997]. 
Interestingly, the gender-specific aspect of AD has recently been linked with 
the processing of APP, suggesting that BACE-activity may be one of the factors 
that contributes to the observed increase in prevalence and incidence of AD in 
women [Schäfer et al., 2007].
Processing of the amyloid precursor protein
APP is a transmembrane protein found mostly at nerve terminals. It is located 
on chromosome 21, contains 770 amino acids, and is ubiquitously expressed 
in all mammalian cells with a high degree of evolutionary conservation. The 
general processing of APP is carried out by two competing pathways, of which 
the amyloidogenic pathway is associated with AD. APP is here initially cleaved 
at the β-secretase site by the β-site cleaving enzyme (BACE), producing a large 
soluble extracellular fragment of APP (sAPPβ), and an Aβ-bearing membrane-
associated C-terminal fragment (CTFβ) of 99 residues. The CTFβ is subse-
quently cleaved within the APP transmembrane domain by the γ-secretase 
complex, composed of at least four integral membrane proteins: presenilins 
(PS1/PS2), nicastrin, Aph1, and Pen2 [Kaether et al., 2006]. The cleavage of 
CTFβ subsequently generates Aβ peptides of varying length (39–43 amino ac-
ids), and a fragment called APP intracellular domain (AICD) (Figure 2).
Interestingly, the localization of CTFβ during cleavage might be the deter-
mining factor for the length of the generated peptide.  The most frequently oc-
curring peptide, Aβ1-40, is generally believed to be generated in the cell mem-
brane, while the more toxic Aβ1-42 peptide is believed to be generated in either 
the endoplasmic reticulum or the golgi complex, early in the biosynthetic path-
way [Klein et al., 1999; Selivanova et al., 2007]. It has recently been proposed 
that newly synthesized APP is subject to amyloidogenic processing during the 
initial phases of the secretory pathway [Selivanova et al., 2007], which might 
be an explanation for the different cleavage sites. In addition, APP processing 
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is highly associated with cholesterol and the cholesterol-rich lipid rafts located 
within the cell membrane [Ehehalt et al., 2003]. Thus, alterations in cholesterol 
transport may have an effect on the localization of the presenilins in the γ-
secretase complex [Runz et al., 2002].
The non-amyloidogenic pathway constitutes an alternative pathway, initi-
ated by the cleavage at the α-secretase site by a member of the ADAM (a dis-
integrin and metalloprotease) family, of which ADAM10, ADAM17 (TACE), 
ADAM9 and ADAM19 have been identified as having α-secretase activity 
[Fahrenholz et al., 2000; Asai et al., 2003]. The cleavage occurs within the Aβ 
region (between residues 16 and 17), thereby preventing the formation of Aβ, 
generating a soluble extracellular fragment of APP (sAPPα), and a membrane-
associated C-terminal fragment (CTFα) of 83 residues. 
The α-secretase cleavage does not only constitute a non-Aβ pathway by the 
cleavage within the Aβ region, but it has also been suggested that α-secretase 
activity occurring in the golgi complex may compete directly with the β-secre-
tase pathway [Skovronsky et al., 2000], and the resulting sAPPα fragment has 
been found to have neurotrophic effects that counteract apoptotic signalling 
and promote synaptogenesis [Selkoe, 2000; Farenholz and Postina, 2006]. 
Cleavage of the sAPPα fragment by the γ-secretase complex generates a short 
peptide fragment (P3) unable to form aggregates, and in parallel with the amy-
loidogenic pathway, an AICD fragment (Figure 2).
Figure 2. Schematic overview of the general processing of the amyloid precursor pro-
tein; the non-amyloidogenic pathway constitutes a ‘non-Aβ’ pathway, with a cleav-
age with the Aβ region, whereas the amyloidogenic pathway generates Aβ peptide of 
lengths between 39–42 amino acids.
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The AICD fragments are believed to be liberated by a final cleavage named 
the ε-cleavage, executed by the γ-secretase complex, [Weidemann et al, 2002]. 
It has been demonstrated that AICD fragments have a transcriptional poten-
tial, with a suggested important function in the regulation of cellular actin dy-
namics [Cao and Südhof, 2001; Müller et al., 2007], but the physiological role 
and target of AICD-dependent gene regulation remain largely unknown. 
Among the well-known mutations in the APP gene, we find the Swedish 
mutation, located close to the BACE cleavage. FAD patients with this inherited 
form of APP have been found to have increased levels of Aβ1-40 and Aβ1-42 in 
plasma [Mullan et al., 1992]. Another mutation of APP that has been associated 
with FAD is the Arctic mutation, located in the Aβ sequence. This mutation 
appears to decrease the production of Aβ whilst enhancing the formation of 
fibrils [Nilsberth et al., 2001].
Amyloid cascade hypothesis
The clinical symptoms and the neuropathological events in both FAD and SAD 
are, according to the amyloid cascade hypothesis, caused by the toxic effects 
of overproduction, aggregation and deposition of Aβ oligomers in neuritic 
Figure 3. Schematic overview of the amyloid cascade hypothesis. The hypothesis sug-
gests that the clinical symptoms and the neuropathological events in AD are caused 
by the toxic effects of overproduction, aggregation and deposition of Aβ oligomers in 
neuritic plaques [Hardy and Higgins, 1992].
Lifelong increase in Aβ production,  
or failure of Aβ clearance
Aβ accumulation and oligomerization
Subtle effects on synapses and cognitive functions
Gradual deposits of Aβ oligomers 
as diffuse plaques
Inflammation, with increased expression  
of inflammatory mediators
Dementia ?
Altered kinase/phosphatase activity
Formation of neurofibrillary tangles
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plaques [Hardy and Higgins, 1992]. It has been demonstrated, under controlled 
conditions, that Aβ1-42 peptides aggregate and create a mixture of Aβ fibrils, 
protofibrils and soluble oligomers [Hartley et al., 1999; Ferrari et al., 2003]; a 
mixture with an established toxic effect on neurons in vitro [Pike et al., 1991]. 
The amyloid cascade hypothesis elaborates that the plaques, with these toxic 
Aβ oligomers, are causing a disruption of synaptic connections; reduction of 
neurotransmitters; activation of glial cells with accompanying inflammatory 
responses; tau phosphorylation; formation of NFTs; and finally dystrophic 
neuritis and neurodegeneration [Hardy and Higgins, 1992] (Figure 3). 
The main objection to the theory of a disturbed Aβ homeostasis as a central 
event in AD is the finding that cognitively intact persons have revealed large 
Aβ deposits at autopsy, without any occurrence of clinical symptoms [Webster 
et al., 1997]. This implicates that solid Aβ depositions (fibril Aβ aggregates) 
alone, are insufficient to cause cognitive decline, and should not be correlated 
with the progression of the clinical disease. Furthermore, the genes required 
for Aβ generation (APP, PS1, and BACE) are expressed at high levels in areas 
that develop senile plaques in AD, but they have also been found at high levels 
in the cerebellum, which only develop insignificant amounts of Aβ depositions 
[Fukumoto et al., 2002]. These results indicate that a hitherto unknown region-
specific factor, or the combined effect of several separate factors, is necessary 
for Aβ deposition and plaque formation to occur. 
Neurofibrillary tangles and tau phosphorylation
The formation of neurofibrillary tangles (NFTs) is caused by an abnormal 
phosphorylation of the microtubule-binding tau protein, which aggregates 
into paired helical filaments (PHFs) in the cytoplasm of degenerating neurons. 
These PHFs are the main constituent of NFTs found within the neuronal peri-
karyon, the neuropil threads and within dystrophic neuritis surrounding the 
plaques. The observation that NFTs have been found in degenerating neurons, 
adjacent to neurons free of any morphological indication of the disease, has led 
to the suggestion that it is the NFTs that are responsible for the synaptic failure 
in AD [Callahan and Coleman, 1995]. 
Tau phosphorylation is regulated by the balance and interaction between sev-
eral kinases and phosphatases [Iqbal et al., 2005], but the molecular mechanisms 
affecting this balance are not fully understood. However, NFTs may occur in a 
number of different neurodegenerative diseases such as AD, Parkinson’s disease 
and Niemann-Pick Type C disease (NPC) [Lee et al., 2001]. These findings imply 
that the abnormal hyperphosporylation of tau, and subsequent occurrence of 
NFTs, may constitute a set of factors, which increase the risk of neurodegenera-
tion, without specifying the exact course of action. Accordingly, the hyperphos-
phorylated tau in NFTs of patients with NPC has been found to be indistin-
guishable from the ones found in AD [Auer et al., 1995; Distl et al., 2003].
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Inflammation and cytokines
The definition of inflammation is a ‘non-specific host response to ubiquitous 
noxious stimuli’. Thus, when we consider the occurrence of an inflammation in 
various neuropathological conditions, we have to consider whether inflamma-
tion and its inflammatory mediators have beneficial or detrimental functions 
or if it may even be an irrelevant observation. Proof in support of the detri-
mental effects is substantial, even though a number of reports have suggested 
otherwise. 
Microglia and astrocytes
The microglia are the resident immune cells of the CNS, and in the healthy 
non-AD brain they are ramified resting cells that have lost their macrophage-
like properties [Nakajima and Kohsaka, 1993; Kreutzberg, 1996]. When an 
injury or a microbial infection occurs, the microglial cells become activated 
with a macrophagic phenotype, proliferation, phagocytosis, and expression of 
MHC-II and antigen presentation [Rogers et al., 1988].
In contrast, the AD brain suffers from a severe chronic inflammation which 
is causing a chronic activation of the injury-responsive microglial cells in the 
vicinity of neuritic plaques [Gordon, 1993; Kalaria et al., 1996; Tarkowski et al., 
2003; Liu and Hong, 2003]. The neuroprotective effects of the inflammation in 
AD have been supported by the finding that Aβ peptides may be phagocyted 
by activated microglia [Mentlein et al., 1998]. Though, it has been suggested 
that the inflammation and presence of microglial activation in AD, is not only a 
reaction to Aβ deposits and neurodegeneration, but that it may also contribute 
to disease progression. Some studies have implied an active role of microglia 
in the mediation of Aβ toxicity and subsequent secondary tissue damage, via 
release of pro-inflammatory cytokines and cytotoxic molecules [McGeer et al., 
1988; McGeer and McGeer, 2004]. Accordingly, it has been hypothesized that 
the inflammation observed in AD is a chronic, self-perpetuating neuroinflam-
mation that stimulates an autotoxic process that aggravates the pathogenic 
mechanism and influences the disease progression [McGeer and McGeer, 
2004]. In another hypothesis, the microglia becomes functionally deficient 
with a subsequent decline in neurotropic support of neurons and impaired 
phagocytic functions, resulting in an excessive release of cytokines and defec-
tive clearance of Aβ deposits [Blasko et al., 2004; Flanary et al., 2007].
Astrocytes are the most abundant glial cells in the CNS and apart from 
producing cholesterol and ApoE, as previously described, they play an essen-
tial role in the maintenance of the BBB integrity and normal brain physiology 
[Rubin and Staddon, 1999]. This role becomes even more evident in light of 
the fact that astrocytes participate in the CNS response to injury [Eng and 
Ghirnikar, 1994; Gustafson et al., 2003]. Accordingly, astrocytic activity and 
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gliosis are associated with cognitive decline and have been described in many 
neurodegenerative diseases, such as AD and Parkinson’s disease [Minagar et al., 
2002; Kashon et al., 2004]. We can define gliosis further and describe it as an 
increased number of hypertrophied astrocytes, positive for the glial fibrillary 
acidic protein (GFAP), a major member of the class III intermediate struc-
tural filament protein and expressed in mature astrocytes [Eng and Ghirnikar, 
1994].
Cytokines in the aging brain
A general decline in immunological regulation is considered to be a hallmark 
in the normal aging process, with an age-associated increase in microglial acti-
vation in cognitive intact patients [Sheng et al., 1998]. Considering that pro-in-
flammatory cytokines is secreted by a wide variety of cells, including microglia 
cells and astrocytes [Benveniste, 1992], it is not surprising that we also find 
an age-associated increase of cytokines correlated with a normal decline in 
cognitive function [Ye and Johnson, 1999; Weaver et al., 2002; Teunissen et al., 
2003]. The cytokine homeostasis is essential for cognitive functions and the cy-
tokines are responsible for a variety of neurotransmitter and neuroendocrine 
responses subserving cognition. It is thus possible that they are liable for a part 
of the normal cognitive decline seen in the aging brain.
The cytokines are suggested to modulate their effects by a complex signal-
ling pathway in which the mitogen-activated protein kinases may phosphory-
late and activate each another. The primary activation of the enzyme p38 is 
mediated by the inflammatory cytokines and environmental stresses; ERK has 
a function in the control of cell division; whereas JNK are a critical regulator of 
transcription [Johnson and Lapadat, 2002]. 
Interleukin-6 and Alzheimer’s disease
Interleukin-6 (IL-6) is a 26,000 kDa pro-inflammatory cytokine involved in 
the regulation of many aspects of the inflammatory and immunological re-
sponses [Taga and Kishimoto, 1997; Dziedzic, 2006]. Findings of IL-6 and IL-6 
receptor mRNA in the pyramidal cells of the rat hippocampus [Minami et al., 
1991], suggest that the cytokine in addition to the previously described expres-
sion by the microglia cells and astrocytes, under certain circumstances can be 
expressed by neurons. Transgenic over-expression of IL-6 in astrocytes has 
been found to cause gliosis and neurodegeneration of hippocampal neurons, 
reduction of dendritic arborisation, angiogenesis and induction of acute phase 
proteins [Campbell et al., 1993], whereas mice with IL-6-deficieny will develop 
mature-onset obesity [Wallenius et al., 2002]. 
In the healthy brain IL-6 are regularly found at low levels [Wilson et al., 
2002], with an age-associated expression as mentioned above. Increased 
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plasma IL-6 levels have been reported in mice and non-demented populations, 
with a correlation to a decline in cognitive function and increased mortality 
[Cohen et al., 1997; Harris et al., 1999; Ye and Johnson, 1999; Weaver et al., 
2002; Teunissen et al., 2003; Yaffe et al., 2003]. These observations are interest-
ing, particularly as the Rotterdam study has demonstrated that plasma levels of 
inflammatory proteins, such as IL-6, are increased before clinical onset of AD 
and vascular dementia, which is consistent with their alleged lesion-promoting 
role [Engelhart et al., 2004]. Consequently, an increased production of pro-in-
flammatory cytokines has been found in the vicinity of neuritic plaques in AD 
patients [Griffin et al., 1989; Bauer et al., 1991; Dickson et al., 1993], whereas 
patients with late-stage dementia demonstrate high levels of cytokine mRNA 
expression in the entorhinal cortex and superior temporal gyrus at autopsy 
[Luterman et al., 2000]. Furthermore, inflammatory mediators are more likely 
to occur in “early” diffuse plaques without neuritic pathology, than in late stage 
“burned-out” plaques [Bauer et al., 1991; Gruol and Nelson, 1997; Fassbender 
et al., 2000]. 
Interestingly, it has been demonstrated that treatment with statins, which 
inhibit the cholesterol synthesis, has the potential to decrease the secretion of 
IL-6 and reduce the cell viability of human microglial cells [Lindberg et al., 
2005], as well as indirectly inhibit the inflammatory response through isopren-
oid depletion [Khwaja et al., 2000]. The isoprenoids are intermediates gener-
ated in the cholesterol biosynthesis pathway and play a significant role in the 
activation of IL-6 mediated inflammation [Heinrich et al., 1998].
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cholesterol
General background
Cholesterol can be found in all human cells where they contribute to the struc-
tural stability of the lipid bi-layers. Although the brain makes up only 2% of the 
human body mass, it is, with 25% of the cholesterol, the most cholesterol-rich 
organ in the body. Here it plays an essential role in maintaining the normal 
physiological conditions of the central nervous system (CNS), a role stressed 
by the fact that it is required for the ability of neurons to communicate. 
The presence of incorporated microdomains, composed of cholesterols, 
sphingolipids and saturated fatty acids, is one of the characterizing features 
of the plasma membranes [Simons and Ikonen, 1997]. These lipid rafts are 
thought to exist as ordered membrane patches, surrounded by more fluid 
membrane mainly composed of glycerolipids. They are believed to have an 
important function in the lateral segregation of membrane proteins, and the 
spatial organization and regulation of membrane proteins involved in many 
cellular processes such as APP processing, cell proliferation, apoptosis, and cel-
lular signalling [Ehehalt et al., 2003; Ma, 2007]. Thus, it has been hypothesized 
that the lipid rafts could be a vital component in the pathogenesis of different 
neurodegenerative disorders. 
In addition to the lipid rafts, cholesterol serves as an important precursor 
and cofactor of several signalling molecules [Tabas, 2002], a barrier against 
sodium leakage [Haines, 2001], and as a required component for the formation 
of synapses [Mauch et al., 2001]. In addition, it has been demonstrated that 
cholesterol is a major component of the myelin sheaths, thus essential for an 
efficient electrical transmission [Dietschy and Turley, 2004]. 
Cholesterol appears in many varieties, for example, LDL (low density lipo-
protein) cholesterol is considered to be increasing the risk for atherosclerosis 
and heart disease, whereas HDL (high density lipoprotein) cholesterol, on the 
other hand, may help to protect the heart and blood vessels, including those 
that supply food and nourishment to the brain. Plasma cholesterol are under 
normal circumstances not able to cross the blood-brain barrier (BBB) [Rubin 
and Staddon, 1999; Pfrieger, 2003], and the cholesterol found in the CNS is 
characterized by a very low turnover. In light of this, it is not surprising to dis-
cover that essentially all cholesterol in the CNS is synthesized in situ, with their 
source of synthesis shifting from the neurons during infancy, to the astrocytes 
in the adult brain [Poirier et al., 1993; Pfrieger, 2003; Brown et al., 2004]. (For a 
overview of the cholesterol synthesis, see Figure 4, page 16.)
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Figure 4. Schematic overview of the cholesterol synthesis. Statins exert their inhibi-
tion on the HMG-CoA reductase, the rate-limiting step, early in the biosynthesis.
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Cholesterol homeostasis in the CNS
In the adult brain, although there is a continuous turnover of membrane, the 
cholesterol is efficiently re-cycled and has a remarkably high half-life up to 5 
years. The homeostasis is maintained by a slow conversion of brain cholesterol 
into the oxysterols 24(S)-hydroxycholesterol (24S-OHC) and 27-hydroxy-
cholesterol (27-OHC) (Figure 5). The conversion is mediated by the two en-
zymes cholesterol 24-hydroxylase (CYP46A1) and cholesterol 27-hydroxylase 
(CYP27A1), with the interesting detail that CYP46A1 only generates the (S)-
stereoisomer of 24-hydroxycholesterol. The oxidation in the steroid side-chain 
dramatically increases the capacity of the generated oxysterols to pass the BBB 
and other lyophilised membranes, resulting in a rapid turnover of the small 
pool of oxysterols out in the circulation [Björkhem et al., 1997; Brown et al., 
2004; Meaney et al., 2007]. The flux of 24S-OHC is considered to be the major 
pathway for excretion of excess cholesterol out of the CNS, with a half-life of 
12 hours [Björkhem et al., 1997; Xie et al., 2003]. 
Immunocytochemical studies have shown that both CYP46A1 and 
CYP27A1 are expressed in neurons as well as by some astrocytes in the healthy 
brain [Lund et al., 1999; Brown et al., 2004]. Not surprisingly, the concentra-
tion of 24S-OHC are 30–1500-fold higher in the brain than in any other organ, 
except the adrenals [Ercoli and Rugieri, 1953; Lütjohann et al., 1996]. In con-
trast, 27-OHC has demonstrated a net flux from the circulation into the CNS, 
by a yet undefined cause, but is found at low levels in the brain due to an active 
metabolism and elimination [Heverin et al., 2005; Meaney et al., 2007]. Inter-
estingly, the regulation of oxysterols seems to have an age-associated factor, as 
Figure 5. Schematic overview of cholesterol (cholest-5-en-3β-ol), 24-hydroxycholes-
terol and 27-hydroxycholesterol. The enzyme CYP46A1 converts cholesterol into the 
S-isomer of 24-hydroxycholesterol, whereas the enzyme CYP27A1 converts choles-
terol into 27-hydroxycholesterol.
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the ratio between 24S-OHC and plasma cholesterol was approximately 5 times 
higher during the first decade of life, than during the sixth decade [Lütjohann 
et al., 1996]. Furthermore, 24S-OHC has in addition to its contribution to 
cholesterol homeostasis been reported as one of the most potent endogenous 
ligands for the liver X receptor, the activation of which has demonstrated to 
have both anti-amyloidogenic and anti-inflammatory effects [Janowski et al., 
1999; Abildayeva et al., 2006; Cao et al., 2007].
Cholesterol and Alzheimer’s disease                
It has been established that cholesterol and hypercholesterolemia are im-
portant risk factors for neurodegeneration [Sparks et al., 1994; Refolo 2000; 
Fassbender et al., 2001; Kivipelto et al., 2001; Puglielli et al., 2003], but the cir-
cumstances surrounding the connection are complicated, and exactly how it is 
manifested is still under debate. It is likely that some of the neuropathological 
changes found in the AD brain are linked with deficiencies in the lipoprotein 
transporter ApoE, implying the importance of a regulated cholesterol homeo-
stasis in the brain. 
Cholesterol has been reported to be required for the production of Aβ pep-
tides [Simons et al., 1998], which has lead to the hypothesis that the amount of 
Aβ in the brain could be decreased, by decreasing cholesterol from the blood 
and the cerebrospinal fluid (CSF) [Buxbaum et al., 2002]. However, the require-
ment of cholesterol in the processing of APP is most likely connected with the 
lipid rafts, which supports the hypothesis that the lipid rafts play a crucial role 
in the cleavage [Ehehalt et al., 2003]. To further complicate the situation does 
the association between plasma total cholesterol (TC) and dementias, appear 
to be both age-associated, and bi-directional; high plasma TC levels in midlife 
is a risk factor for subsequent dementia and AD [Kivipelto et al., 2001; Solo-
mon et al., 2007], wheras the decreasing plasma TC levels after midlife can be 
regarded as a sign of the underlying disease processes, and as such represent a 
potential marker for late-life cognitive impairment [Solomon et al., 2007].
The task to evaluate cholesterol levels in the brain represents another chal-
lenge. It has been demonstrated that the cholesterol homeostasis is disturbed 
in AD patients, with decreased levels of 24S-OHC and increased levels of 27-
OHC in the brain [Heverin et al., 2004; Björkhem et al., 2006]. The reason for 
these changes could be a directly relationship with the decreased metabolic 
activity in the CNS due to the neurodegeneration; the decreased number of 
metabolic active neuronal cells affects the production of 24S-OHC and the 
elimination of 27-OHC. Among previously reported and yet not satisfyingly 
explained observations, we find a study in which patients with AD were found 
to exhibit a selective expression of CYP46A1 around neuritic plaques and in 
astrocytes, whereas CYP27A1 expression was found to be decreased in neu-
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rons and around the plaques [Brown et al., 2004]. A possible explanation for 
these findings could be that they indirectly reflect the disease process, and what 
we see is a feed-back regulation in response to the altered cholesterol homeo-
stasis. 
Cholesterol and APP processing
The processing of APP is, as previously described, a requirement for the onset 
and progression of AD. An increased BACE activity can be found even in the 
healthy brain as a natural consequence of aging [Fukumoto et al., 2004], but 
AD patients demonstrate a significantly higher activity [Li et al., 2004]. 
The BACE complex undergoes a sequence of events for dimerization and 
stabilization within the membrane to occur, such as farnelysation and palmi-
toylation. They provides BACE both directly and indirectly with the two lipid 
anchors commonly found in membrane-bound proteins, and needed for the 
recruitment into the lipid rafts [Zhang and Casey, 1996; Westmeyer et al., 2004; 
Schmechel et al., 2004; Parsons et al., 2006]. The order of assembly of the BACE 
complex suggests that a reduction in membrane cholesterol could result in an 
inhibition of the dimerization of BACE. This would prevent BACE from enter-
ing the lipid rafts; reduce its association with the APP, and as a consequence, 
result in a decreased Aβ production [Parsons et al., 2007]. Noteworthy is the 
finding that cholesterol distribution – rather than total levels – has been cor-
related with altered APP processing after treatment with statins [Burns et al., 
2006]. The connection could be the previously described association between 
the processing of APP and the lipid rafts [Ehehalt et al., 2003]. 
It has also been demonstrated that the intracellular cholesterol transport has 
important consequences for both APP processing and the localization of the 
γ-secretase associated presenilins, and could be an important factor for how 
cholesterol alters Aβ production [Runz et al., 2002]. 
Cholesterol and Apolipoprotein E
The lipoprotein transport is maintained by the apolipoproteins of which pri-
marily apolipoprotein E (ApoE), produced by the glial cells, has an important 
function in the CNS not only for lipid transport, but also for maintenance and 
repair of neurons. Human ApoE is a polymorphic protein, 299 amino acids 
long and located on chromosome 19. Interestingly, the genetic polymorphisms 
of ApoE have been found to be among the strongest determinants of the risk 
and mean age of onset of SAD [Saunders et al., 2003]. It encodes three alleles 
that differ only at two positions; 112 and 158. ApoE ε2 has cysteines at both 
positions and occurs at a frequency of 5%–10%. ApoE ε3 occurs in 60%–70% 
of the population and has cysteine at 112 and arginine at 158. The detrimental 
ApoE ε4 has arginine at both sites and occurs in 15%–20% of all humans, with 
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an increased risk of approximately 300% for developing AD [Buxbaum, 2002]. 
Of great concern is the finding that the risk is age-associated, with a significant 
risk only below the age of 80 years [Dupuy et al, 2001]. This finding suggests 
that the connection between AD and ApoE ε4 is most important during the 
initial and middle stages of the disease. It has been suggested that the reason 
why ApoE ε4 persists in our genome, despite its detrimental effects, is the pos-
sibility that it may confer advantages in pathogen resistance [Charlesworth, 
1996; Finch and Morgan, 2007].
The presence of ApoE ε4 has been associated with an increased concentra-
tion of cholesterol in the plasma [Notkola, 1998; Buxbaum, 2002], and an in-
creased concentration of 24S-OHC in the CSF [Papassotiropoulos et al., 2002], 
while ApoE deficiency has been found to dramatically reduce the Aβ deposi-
tion [Bales et al., 1997]. 
The connection between ApoE-deficiencies, cholesterol and AD has been 
studied using ApoE knockout (-/-) mice, originally developed for studies on 
the pathogenesis of atherosclerosis, with a 5–10 fold increase in plasma choles-
terol levels [Zhang et al., 1992]. It has also been hypothesized that an age-relat-
ed BBB leakage is associated with ApoE deficiency, and that it could be one of 
the mechanisms linking ApoE ε4 with plasma cholesterol and the progression 
of AD [Hafezi-Moghadam et al., 2007], without influencing the transport of 
Aβ across the BBB [Matsumoto et al., 2007]. Accordingly, it has been reported 
that ApoE-/- mice provided with a high cholesterol (HC) diet have increased 
tau hyperphosphorylation and gliosis with increased levels of inflammatory 
mediators such as IL-6 and caspase-1 [Crisby et al., 2004; Rahman et al., 2005.a; 
Rahman et al., 2005.b].  
The connection between cholesterol and apoptosis is supported by a signifi-
cant increase of apoptotic cells and caspase-3 activity in AD patients bearing 
one or two alleles of the ApoE ε4, compared to non-ε4 carriers [Frey et al., 
2006]. The connection might be explained by an association with the lipid rafts 
and the hypothesis that ApoE ε4-carriers are awarded with excessive amounts 
of cholesterol in the plasma membranes. Furthermore, it has been suggested 
that the some of the detrimental effects of ApoE ε4 are related to the inability 
of the isoform to interact with the microtubule associated protein tau, and 
thereby prevent its hyperphosphorylation. In support of this theory, it has been 
demonstrated that ApoE-/- mice have increased levels of phosphorylated tau in 
association with dietary cholesterol [Genis et al., 1995; Rahman et al., 2005.a].
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treatment strategies 
General introduction
It is currently possible to decrease the symptoms of AD, and improve the pa-
tients’ quality of life, within a few weeks. However, the majority of treatments is 
given first when the disease has progressed to the point of diagnostic certainty, 
and is purely symptomatic anti-dementia drugs without profound disease-
modifying effects. Treatments with cholinesterase inhibitors may delay the 
breakdown of the neurotransmitter acetylcholine in the cortex and, thus, aid 
the preservation of memory function, decrease the degeneration of cognitive 
symptoms and reduce behavioural problems, whereas an alternative treatment 
for moderate to severe AD use a NMDA (N-methylD-aspartate) antagonist 
acting on glutamate, to reduce neuronal death. 
Recent research on AD has focused on the possibilities to affect the pro-
gression of the disease using prevention strategies and modulations of specific 
aspects of the AD pathology, such as; APP processing and secretase inhibition; 
Aβ-aggregation inhibition; vaccination studies; and immunotherapy [Ohno, 
2006; Na et al., 2007; Chauhan and Siegel, 2007; Nikolic et al., 2007]. The as-
sociation between AD and inflammation has been examined using non-steroi-
dal anti-inflammatory drugs (NSAIDs). The Rotterdam study suggested that 
NSAIDs can delay, or slow, the progression of AD with a protective effect up to 
80% [in t’ Veld et al., 2001], but reports from other trials have yielded incon-
clusive results [Akiyama et al., 2000; Aisen et al., 2003; McGeer and McGeer, 
2007]. 
The connection between AD, diet, cholesterol and lifestyle factors has been 
examined in a number of investigations [Kivipelto and Solomon, 2006; Weih et 
al., 2007; Solomon et al., 2007]. The results have been unanimous in support of 
a strong association, which implies that relatively simple modifications could 
be an effective treatment. Among these modifications cholesterol-lowering 
therapies, with a focus on statins have, in particular, attracted rigorous atten-
tion [Sparks et al., 1994; Simons et al., 1998; Fassbender et al.,2001; Puglielli et 
al., 2003; Sparks et al., 2006]. The outcome has been debated, but contradictory 
results may in part be due to the different properties of the statins working in 
conjunction with other factors, such as the severity of the disease and the ApoE 
phenotype.
The majority of all AD patients are diagnosed very late in life, and it could 
be an acceptable solution for an increasingly aging population, if possible, to 
simply delay the symptoms. It has, in agreement with this suggestion, been hy-
pothesized that if the onset of the disease could be delayed by just 5 years, the 
incidence would be cut by 50% [Pasinetti et al., 2007].
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Cholesterol-lowering therapy
The association between cholesterol-lowering therapy and dementia has been 
supported by numerous studies [Simons et al., 1998; Fassbender et al., 2001; 
Puglielli et al., 2003; Sparks et al., 2006], including the observation that animals 
undergoing accelerated aging have improved memory when they are fed a diet 
that lowers their cholesterol [Chan et al., 2002]. These findings suggest that 
memory and cognitive functions during aging could benefit from a choles-
terol-lowering therapy.
Statins
Statins were first introduced into clinical practice in the late 1980s after the 
accidental discovery of their lipid-lowering effects in 1976 [Endo et al., 1976]. 
The effect is exerted by an up-regulated expression of the LDL-receptor in 
the liver, which clear LDL-cholesterol and its precursors from the circulation 
[Brown and Goldstein, 1981]. This effect is in turn caused by the competitive 
inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) re-
ductase, the rate-limiting step early in the synthesis of cholesterol and many 
other non-steroidal isoprenoid compounds (Figure 4, page 16). 
The first statins were produced from fungal metabolites, but the majority 
is now produced synthetically. Accordingly, the traditional method differenti-
ates the two types and classifies them as either natural (fungal metabolites) 
or synthetic. Another classification defines the statins by their solubility: i.e. 
hydrophilic (rosuvastatin, pravastatin, fluvastatin to some extent) or lipophilic 
(atorvastatin, simvastatin, lovastatin, cervistatin). The lipid bi-layers of the cell 
membranes are easily penetrated by lipophilic compounds, whereas the uptake 
of hydrophilic compounds needs to be facilitated by organic anion transport-
ers [Tamai, 2000; Simonson, 2004]. Accordingly, the lipophilic statins may 
cross the BBB and have been demonstrated to cause apoptosis in a variety of 
cells [Negre-Aminou et al., 1997; Kubota et al., 2004], whereas the hydrophilic 
statins do not [Harrison and Ashton, 1994; Knopp 1999]. With this is mind, the 
question have been raised if not hydrophilic statins should to be recommended 
for treatment purposes [Sparks et al., 2002], particularly as it has been demon-
strated that hydrophilic statins exert effects on the CNS despite their inability 
to cross the BBB [Kilic et al., 2005].
Clinical studies on statins have produced some promising but contradictory 
results. On one hand the use of statins failed to prove a significant association 
with maintenance of cognitive function in patients with AD [Winblad et al., 
2007; Summers et al., 2007], whereas, on the other hand, treatment with statins 
has been significantly associated with a decreased prevalence of AD [Wolozin 
et al., 2000]. Statins have also been found to significantly increase the α-secre-
tase activity [Paper II, Xiu et al., 2006], and decrease the levels of both Aβ1-42 
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and Aβ1-40 [Fassbender et al., 2001; Simons et al., 2002]. Of utmost interest is 
the notion that decreased levels of Aβ1-40 in the CSF were restricted to patients 
with mild AD, as no effect was observed in patients with more severe forms of 
AD [Simons et al., 2002]. 
Rosuvastatin
Rosuvastatin is one of the most recently approved statins for clinical use and 
has a structure similar to that of other synthetic statins. It has a long half-life 
of 20–24 hours (comparable to atorvastatin); it is hydrophilic (equivalent 
with pravastatin); and has no significant cytochrome P450 drug interactions. 
In addition, the safety of rosuvastatin at low doses has been reported to be 
comparable to that of other statins [Stein, 2003], and the lack of cytochrome 
P450 metabolism suggests that the therapy may be used without precautions 
in patients who are on CYP3A4 inhibiting drugs. The STELLAR study group 
has demonstrated that rosuvastatin is more efficient than equivalent doses of 
atorvastatin and simvastatin to lower the levels of LDL-cholesterol, with a ben-
eficial effect not only on AD but also on the metabolic syndrome [Jones et al., 
2003; Deedwania et al., 2005].
Pleiotropic effects
All statins have structural similarities, but they also have structural differences 
that may influence their pleiotropic effects. The primary cause behind these 
mechanisms is believed to be a reduction in protein isoprenylation, which is 
regulated independently of the cholesterol levels (Figure 4, page 16). The pleio-
tropic effects include a stimulated nitric oxide expression through an up-regu-
lated expression and activity of endothelial nitric oxide syhthase [Kalinowski 
et al., 2002]; anti-inflammatory effects through an attenuation of mediators 
of inflammation and immunological responses [Kleeman et al., 2003; Wagner 
et al., 2002]; anti-oxidant effects through a reduction of lipoprotein oxidation 
[Crisby et al., 2001]; stabilization of atherosclerotic plaques [Crisby et al., 
2001]; and some anti-angiogenic effects [Vincent et al., 2001]. 
The pleiotropic effects on inflammation have been supported by the finding 
that statins exert an effective inhibitory effect on MHC-II expression [Kwak, 
2000], particularly interesting as MHC-II molecules are directly involved in 
the control of the immune system. Furthermore, rosuvastatin has been report-
ed to reduce the caspase-3 levels in ischemic brain areas [Kilic et al., 2005], and 
the formation of dolichols which have an essential role in lipoprotein synthesis 
[Faggiotto and Paoletti, 2000].
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Lifestyle factors
Obesity and diabetes is associated with a >4-fold increased risk of develop-
ing AD [Pasinetti et al., 2007], and both clinical and epidemiological evidence 
suggests that modifications of lifestyle factors such as diet and nutrition may 
prove crucial for the onset of AD. The importance of diet is emphasized by the 
findings that diets based on saturated fats may decrease learning and memory, 
increase oxidative stress and support Aβ load [Winocur and Greenwood, 1999; 
Pinilla, 2006; Pasinetti et al., 2007], whereas diets supplemented either with 
omega-3, vitamin E or the curry spice curcumin may be beneficial for cogni-
tive functions [Pinilla, 2006]. Dietary supplementation of curcumin has also 
been found to counteract the outcome of traumatic brain injury on oxidative 
stress, synaptic plasticity, and cognition [Wu et al., 2006]. In a recent clinical 
trial on the use of omega-3, a significant effect on cognitive decline was only 
observed in a small group of patients with very mild AD [Freund-Levi et al., 
2006], whereas an ApoE ε4-dependent effect on neuropsychiatric symptoms 
was observed in mild to moderate AD [Freund-Levi et al., 2007].
However, given the fact that our metabolism changes with age, and that sev-
eral medications interfere with the absorption of nutrients, diet alone may not 
be a clinically useful treatment in elderly people. Short-term effects of a healthy 
lifestyle have been evaluated in a 14-day clinical study, regarding cognition and 
cerebral metabolism in people with mild age-related memory complaints. The 
program combined diet with other lifestyle factors, such as relaxation exercises, 
cardiovascular conditioning and mental exercises (i.e. brain teasers and verbal 
memory training techniques). The result of this so called short-term healthy 
lifestyle program was an association between the program and significant posi-
tive effects on cognitive function and brain metabolism [Small et al., 2006]. 
These findings suggest that it may be possible to prevent early memory defi-
ciencies by a combination of relatively simple methods. 
Caloric restriction
Caloric restriction (CR) has re-emerged as a remarkable strategy, if properly 
executed and precautions are taken to avoid malnutrition. It has been reported 
that if it is initiated during midlife, it can result in significantly decreased meta-
bolic risk factors and a substantial longevity benefit independent of the effects 
on reproductive capabilities [Kaerberlein et al., 2006; Holloszy and Fontana, 
2007]. 
The effects induced by CR include a potential protection of neurons against 
excitotoxic and metabolic insults [Mattson et al., 1997]. CR may also have a 
preventive effect on Aβ generation and subsequent Aβ depositions, through 
mechanisms associated with α-secretase activity and the non-amyloidogenic 
pathway [Wang et al., 2005; Pasinetti, 2007]. 
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The general aim of this thesis was to study the effects of cholesterol and cho-
lesterol-lowering therapy with rosuvastatin, on key factors associated with 
Alzheimer’s disease.
The specific aims were as follows:
• To investigate the effects of 24(S)-hydroxycholesterol, 27-hydroxycholester-
ol and cholesterol 24-hydroxylase, on the processing of the amyloid precur-
sor protein in human neuroblastoma SH-SY5Y cells, with focus on α- and 
β-secretase activity, and levels of soluble APPα and total soluble APP.
• To investigate the effects of pre-treating human neuroblastoma SH-SY5Y 
cells with rosuvastatin prior exposure to toxic aggregates of Aβ1-42 oligo-
mers, on neurodegeneration and the processing of the amyloid precursor 
protein, with focus on caspase-3 and α-secretase activity. 
• To investigate the effects of rosuvastatin on inflammation in WT and 
ApoE-/- mice provided with high levels of dietary cholesterol for 18 weeks, 
with focus on gliosis, presence of activated microglial cells and levels of the 
pro-inflammatory cytokine interleukin-6 in plasma and brain tissue.
• To investigate the effects of rosuvastatin on lifestyle risk factors in WT and 
ApoE-/- mice provided with high levels of dietary cholesterol for 18 weeks, 
with focus on body weight gain, plasma cholesterol and plasma lipoprotein 
levels.

29Materials and Methods
paper i–ii
Cell culture conditions, reagents and treatments 
Human neuroblastoma SH-SY5Y cells were cultured in 60-mm cell culture 
dishes using Dulbecco’s Modified Eagle’s Medium:Ham’s F12 (DMEM:F12; 
1:1; v/v) with Glutamax (paper I) or 365 μg/ml L-Glutamine and 50 μg/ml 
Gentamicin (paper II), and 10% (v/v) fetal bovine serum (FBS). All media, 
supplements and reagents were obtained from Gibco Invitrogen unless other-
wise stated. Cells were plated at 5 x 104 cells/well into 96 well microtiterplates 
(Nunc), at 0.5 x 106 cells/dish into 60 mm culture dishes (Corning Costar) or 
at 10 x 104 cells/well on 8 well culture slides (Becton Dickinson, Falcon), and 
allowed to adhere. The cells were cultured for 6–7 days under non-differenti-
ated conditions, until a confluence of 80% was achieved. The Trypan Blue Stain 
assay was used to count the cells and evaluate their viability as a percentage 
between viable and non-viable cells. The viability of cells was >97% prior ex-
perimental procedure. All cultures and incubations were kept in a humidified 
incubator at 37°C, 5% CO2. Serum-free DMEM:F12 without antibiotics was 
used during all treatments and cells incubated without any treatment were 
used as control. Protein quantifications were made using the BCA protein as-
say (Pierce Biochemicals).
To the cell culture study in paper I we obtained purified 24S-hydroxycholes-
terol (24S-OHC) from Bio-Nuclear Scandinavia AB and 27-hydroxycholesterol 
(27-OHC) from Steraloids. A stock of each oxysterol was prepared in ethanol 
and stored in the dark at -70°C. The cells were incubated with hydroxycholes-
terol by incubation for 24 hours at 37°C in serum-free medium with 24S-OHC, 
27-OHC or a mixture of 24S-OHC and 27-OHC (1:1) to a final concentration 
of 5 µM/mL.
The synthetic peptide Aβ1-42 used in paper II was obtained from US Pep-
tide Inc. A stock solution (25 μM) was dissolved in serum-free medium and 
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incubated for 24 hours at 37°C in a sealed tube to allow self-aggregation and 
oligomerization. Rosuvastatin Calcium was provided by AstraZeneca (UK). 
DL-Mevalonate Acid Lactone (mevalonate) was purchased from Sigma-Al-
drich. Stock solutions of rosuvastatin (200 μM) and mevalonate (4 mM) were 
dissolved in serum-free medium and mixed thoroughly immediately before 
treatment of the cells. SH-SY5Y cells were pre-treated with 20 μM rosuvastatin 
for a period of 24 hours, before exposure to 2.5 μM Aβ1-42 alone or concurrent 
with 400 μM mevalonate for a period of 24 hours.
Cell culture transfection with CYP46 
The SH-SY5Y cells in paper I were transfected with the complete open reading 
frame of cholesterol 24-hydroxylase of either human (CYP46A1) or murine 
(CYP46a1) origin, under the control of a viral promoter, using Lipofectamine 
2000. A 1:1 ratio of DNA:Lipofectamine was used in all transfections. The cells 
were transfected and allowed to recover for 72 hours at 37°C in DMEM:F12 with 
Glutamax and 10% FBS. To ensure that the effect was specific for the introduced 
plasmid, and not merely the addition of DNA, or cationic lipids (i.e. the transfec-
tion reagent), we performed control experiments using an unrelated plasmid (the 
commonly used reporter plasmid pGL3-basic=mock) or crude lipofectamine.
Determination of α- and β-secretase activity 
We determined the α- and β-secretase activities using a Fluorometric α- and 
β-Secretase Activity Kits obtained from R&D Systems. The cell culture treat-
ments described above in paper I, were lysated using 2 mL of cell extraction 
buffer, centrifuged at 10.000 x g for 1 min at 4°C and 500 µl of the supernatants 
was removed. In paper II the cells were lysated with a repeated freeze-thaw 
cycle for 15 minutes, and the supernatants were collected by centrifugation at 
10.000 x g for 15 min at 4°C and stored at -70°C. The supernatants were trans-
ferred (50 µL/well; 50 µg total protein) to a 96-well microplate (Nunc F16 Black 
MaxiSorpTM, Nunc), with 50 µL 2× reaction buffer and 5 µL substrate added 
to a volume of 105 µL. The substrate consisted of the APP peptides YEVH-
HQKLV (α-secretase) and REEVNLDAEFKR (β-secretase) respectively, using 
the reporter system EDANS/DABCYL. The plate was sealed with a plastic film, 
gently mixed by tapping and incubated in the dark for 2 hours at 37°C. The 
fluorescent emission from EDANS was analyzed and measured at λ = 345 nm 
(excitation) and λ = 500 nm (emission). High fluorescence was correlated with 
high enzymatic activity. Measurements were performed using a Safire II mi-
croplate reader with Magellan PC software (v6.2; Tecan Austria Gmbh) at 37°C 
(paper I), or a FLUOstar Galaxy (BMG Labtechnologies Inc) at 37°C (paper II). 
Recombinant human TACE (0.5 μg/ml), generously provided by R&D Systems, 
was used as the positive control in paper II.
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Sample preparation for ELISA analysis of sAPP
Cells at 80% confluence (equivalent to approximately 1x107 cells per plate) 
were treated with the oxysterols as described above in paper I, with the me-
dium removed and saved for ELISA analysis. The cells were rinsed with 5 mL 
PBS pH 7.4 and solubilized in 500 μL lysis buffer (1x Protease inhibitor com-
plete (Roche) and 1% Triton  (Sigma-Aldrich) diluted in PBS pH 7.4). Follow-
ing incubation at 4°C for 20 minutes the cell lysates were collected, mixed and 
centrifuged at 13.000 x rpm for 10 min at 4°C. The supernatants, containing the 
released proteins, were saved at -20°C until required for ELISA analyses. The 
protein contents of the cell lysates were measured by DC protein assay accord-
ing the instructions of the manufactures (BioRad).
Double-antibody sandwich ELISA analysis of sAPPα
150 µL of the rabbit polyclonal antibody, AB5076 (Chemicon) 1:40.000, were 
diluted in a coating buffer (0.05 M carbonate-bicarbonate buffer, pH 9.6), used 
to coat the individual wells of the 96-well microtiter plates (Immuno Modulies, 
Maxisorp, Cert Nunc 469949, VWR).  Incubation was performed over night 
at 4°C by shaking. The coating buffer was then discarded and the wells were 
blocked with 250 μL/well blocking buffer (5% bovine serum albumin (BSA) in 
coating buffer) and incubating for 2 hours at RT by shaking horizontally. The 
blocking buffer was discarded and the wells were washed 3 x with 300 μL TBS-
T (0.05% Tween 20, 0.01% NaN3 [26628-22-8] (Sigma-Aldrich), in TBS pH: 
7.4) buffer. Either 150 μL cell medium or 75 μL cell lysate from cells treated as 
described above in paper I was added to the wells and incubated over night at 
4°C by shaking. These antigens were then discarded and the wells were washed 
two times with 300 μL/well PBS, pH: 7.4. 
Soluble APPα (sAPPα) was detected by applying 100 μL/well of the mouse 
monoclonal antibody against human sAPP (Chemicon) 1:5000, diluted with 
TBT-T-BSA (0.1% BSA, 0.05% Tween 20, 0.02% NaN3, in TBS). The plate was 
then incubated over night at 4°C. The detection antibodies were discarded and 
the wells were washed 3 x with 300 μL/well PBS-T. 150 μL/well of the alkaline 
phosphate labelled bovine anti mouse IgG antibodies, 1:2500 diluted in TBT-
T-BSA (sc-2377, Santa Cruz Biotechnology) was applied and incubated 2.5 
hours at RT. The wells were washed 3 x with 300 μL with TBS-T. 200 μL/well 
Substrate (4-Nitrophenyl phosphate-Na2-6H2O, Fluka, Biochemica, [71770]) 
diluted in DEA buffer (1M Diethanolamine, 0.5M MgCl2. 6H2O, 0.01 % NaN3 
in H2O pH to 9.8) was applied and incubate at RT for 2.5 hours in darkness 
Absorbance was measured at A405 nm using a Safire II microplate reader with 
Magellan PC software (v6.2; Tecan Austria Gmbh) at 37°C. All measurements 
were calculated as percentage of control.
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Direct ELISA analysis of total sAPP 
In contrast to the Double-antibody sandwich ELISA, plate wells were also 
coated directly, with either 150 μL cell medium, or 75 μL cell lysate from cells 
treated as described above in paper I, and incubated over night at 4°C. Using 
the mouse monoclonal antibody against human sAPP and method to measure 
absorbance described above, we were able to detect total sAPP in these wells. 
Determination of Caspase-3 activity
The caspase-3 activity was determined in paper II using a modified colorimet-
ric assay (CaspACE™ assay, Promega). The caspase-3 specific cleavage at the 
C-terminal side of the aspartate residue of the amino acid sequence DEVD 
(Asp-Glu-Val-Asp) was measured using the Ac-DEVD-pNA (chromophore; 
p-nitroaniline (pNA)) substrate. The cell culture treatments described above 
in paper II were lysated with a repeated freeze-thaw cycle for 15 minutes after 
which the supernatants were collected by centrifugation at 10.000 x g for 15 
min at 4°C and stored at -70°C. The supernatants were mixed individually and 
transferred (20μl/well; 20 μg total protein) to a 96 well microtiterplate (Nunc), 
with 32 μl of Caspase assay buffer, 2 μl DMSO, 10 μl DTT (100 mM), 2 μl Ac-
DEVD-pNA Substrate (10 mM) and ddH20 added to a final volume of 100 μl. 
The plate was sealed with a plastic film, gently mixed by tapping, and incubated 
over night at 37°C, 5% CO2. Absorbance was measured at A405 nm for the 
free pNA products and corrected against the blank using a Safire II microplate 
reader with Magellan PC software (v6.2; Tecan Austria Gmbh) at 37°C. All 
measurements were calculated as percentage of control, with high absorbance 
correlated with high activity of caspase-3.
Visualization of non-viable cells 
The fluorescent dye propidium iodide (PI), used in paper II to identify necrotic 
cells and cells  in the late stages of apoptosis, was obtained from Sigma-Aldrich. 
Cells cultured on 8 well culture slides were treated as described above and 
washed with 300 μl cold PBS (phosphate buffered saline), exposed to 200 μl PI 
(1.0 mg/ml), incubated for 15 min at 37°C, washed twice with 200 μl cold PBS 
and mounted with fluorescent mounting medium (Dako, Denmark). Nuclei 
of non-viable cells with damaged membrane were stained red with propidium 
iodide, indicating that the dye had intercalated with cellular DNA. Visualiza-
tion and photography was performed using a Nikon Eclipse E800 fluorescence 
microscope and a Nikon FDX-35 digital camera connected to a PowerMac 
computer with Open Lab (v2.1.0) image processing software (Improvision). 
The controls were used to analyze auto fluorescence and any spontaneous neu-
rodegeneration.
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Determination of cell viability (MTT assay)
The cell viability and metabolic activity reported in paper II, was analyzed using 
a MTT assay obtained from Roche Diagnostics Scandinavia, which measures 
the ability of mitochondrial dehydrogenase to form formazan through cleavage 
of the tetrazolium ring of MTT. Cells cultured in 96 well microtiterplates were 
treated as described above. 0.5 mg/ml MTT labelling agent dissolved in phos-
phate buffered saline (PBS) was added to each well and incubated for 4 hours 
in a humidified atmosphere at 37°C, 5% CO2. The formed formazan crystals 
were dissolved by the addition of 100 μL of 10% SDS in 0.1 M HCl and incu-
bation over night in a humidified atmosphere at 37°C, 5% CO2. Absorbance 
was measured at A570 nm and A670 nm, using a Safire II microplate reader 
with Magellan PC software (v6.2; Tecan Austria Gmbh) at 37°C (paper I), or a 
SpectraMax 250 (Molecular Devices) at 37°C (paper II). Optical imperfections 
in the microplate were corrected by the formula: A570 nm - A670 nm. Absor-
bance was correlated with high activity of live mitochondria and was used as a 
measurement of cell viability. All measurements were calculated as percentage 
of the controls. 
Statistical analysis
Data was checked for normality and analyzed for statistical significance using 
Student’s t-test and analysis of variance (ANOVA). Statistical significance was 
determined at p < 0.05. Homogeneity of variance was tested by Levene’s test. 
Statistical analysis was performed using Statistica PC software (v.6.0; StatSoft). 
All values are expressed as percentage of the mean value of the control group 
± SEM.
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paper iii–iv
Animal models and experimental treatments 
Weight-matched littermates of C57BL/6/Bkl wild-type mice (WT; n=18) 
and B6.129P2-ApoEtm1Unc N11 apolipoprotein E knockout mice (ApoE-/-; 
n=18), were obtained from Scanbur BK and Taconic Europe respectively. All 
animals were housed in the accredited animal facility at the Karolinska Uni-
versity Hospital Huddinge, in standard M2-cages at a constant temperature of 
24–26°C under controlled lighting conditions, with food and water available 
ad libidum. The animals were conditioned during four weeks prior to the on-
set of the study. Experimental treatment was initiated at 14 weeks of age (n=6 
mice/group) and withheld for 18 weeks: high cholesterol (HC) diet also known 
as western diet (R638 [15.6 MJ/kg; nitrogen-free extract (NFE) 43.9%, fat 
21.0%, protein 17.2%, H2O 10.0%, fibres 3.9%, ash 4.1%]; Lactamin), HC diet 
with rosuvastatin treatment (HCRS) and normal diet (ND). Rosuvastatin was 
kindly provided by AstraZeneca (UK). The mice on ND were used as a control 
group. Rosuvastatin was provided in the drinking water at a concentration of 
0.5 mg/kg body weight/day. The volume of the drinking water consumed was 
monitored to ensure that the dose received was as indicated above. Ethical con-
sent was granted by the local regional ethics committee prior to the onset of the 
study. Body weight measurements were performed once weekly. The percent 
gain in body weight was calculated using the body weight values at the time of 
euthanasia, compared with body weight values prior to treatment. The animals 
were anaesthetized with an intraperitoneal injection of sodium pentobarbital 
(600 mg/kg body weight; Apoteket), after which plasma samples (600 µl/mice) 
were collected in a separation tube (BD Microtainer PST LH; Becton Dickin-
son), through puncture of the left ventricle of the heart and stored at -70°C 
until further analysis. Immediately after euthanasia, the brains were removed 
and snap-frozen in -40°C isopentane for 15 sec and stored at -70°C.
Tissue sectioning
Coronal sections 14 µm thick were processed using a cryostat (Microm HM 
500 M) at -20°C, from -2.80 mm posterior to bregma according to the ste-
reotaxic coordinates given by the mouse brain atlas [Paxinos and Franklin, 
2004]. The sections were dried overnight at 4°C and fixed in acetone at room 
temperature (RT) for 10 min, dried at RT for 15 min and stored at -20°C until 
immunohistochemical analysis. 
Immunohistochemical analysis
The frozen sections were briefly dried at RT for 2 min, rehydrated in PBS and 
incubated at RT for 10 min in a dark chamber with 0.3% H2O2 in Methanol. 
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Non-specific binding was inhibited by incubation at RT for 10 min with 1% 
Bovine Serum Albumin, Fraction V (BSA; Sigma-Aldrich). The sections were 
subsequently washed with PBS at RT for 10 min and incubated overnight in a 
dark humidified chamber at 4°C with antibodies against GFAP (1:2000; Z0334; 
Dako; paper III), microglia F4/80 (1:100; MCA479B; AbD Serotec; paper IV) 
or IL-6 (1:300; PM626; Pierce Endogen; paper IV) in 1% BSA. All sections 
were kept in a dark humidified chamber at 4°C. The sections was rinsed with 
PBS and incubated at RT for 30 min with respective biotinylated secondary 
antibodies (1:300; Dako). After washing with PBS, the antigen-antibody com-
plexes were visualized by incubation at RT for 60 min with an avidin-biotin 
horseradish peroxidase complex (ABComplex/HRP; Dako). They were rinsed 
in PBS, exposed to diaminobenzidine (DAB; Sigma-Aldrich), rinsed again in 
ice-cold PBS, until the reaction stopped, and mounted with an aqueous mount-
ing medium (S3025; Dako). Sections incubated in the absence of the primary 
antibody or with immunoglobulin fractions (1:300; Dako), served as negative 
controls.
Cell count for cells labelled with GFAP, was calculated from three randomly 
selected areas in the CA1 field of the hippocampus (paper III). Cell counts for 
cells labelled with F4/80 or IL-6, was calculated from three randomly selected 
areas in the capsula externa (paper IV). All calculations were made using a 
standardized counting grid (0.24 x 0.24 mm) at 40x magnification. Each mea-
surement was repeated three times. Only cells with a distinct staining of the 
cytoplasm and a discernable nucleus were counted. Cells edging the upper and 
left grid lines were included, whereas cells edging the bottom and right lines 
were excluded from the counts. The counting was performed blinded. The re-
sults were calculated using the mean number of counted cells from each mouse 
(n=5 mice/group), translated to cells/mm2 using the known grid area.
Determination of plasma lipoproteins levels
Plasma from each mouse was sampled prior to sacrifice. Plasma total-choles-
terol (TC) and high-density lipoprotein (HDL) levels were measured using 
enzymatic techniques (Hitachi 917). Low-density lipoprotein (LDL) was cal-
culated according to the Friedewald’s Formula. 
Determination of plasma IL-6 levels by ELISA
The plasma levels of IL-6 in paper IV, were analysed from 50 µl blood samples 
withdrawn prior to sacrifice, using an IL-6 ELISA Kit (EM2IL6; Pierce, Endo-
gen). The samples were incubated on an anti-mouse IL-6 pre-coated 96-well 
strip plate according to the instructions from the manufacturer, and visual-
ized with streptavidin-HRP and a TMB substrate solution. Absorbance was 
measured at A450 nm and A550 nm using a Safire II microplate reader with 
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Magellan PC software (v6.2; Tecan Austria Gmbh). Optical imperfections in 
the microplate were corrected by the formula: A450 nm - A550 nm. The amount 
of mouse plasma IL-6 (pg/mL) was determined using a standard curve.
Statistical analysis
Data were checked for normality and analyzed for statistical significance using 
Student’s t-test and analysis of variance (ANOVA). Statistical significance was 
determined at p < 0.05. Homogeneity of variance was tested by Levene’s test. 
Spearman’s non-linear correlation was used to calculate the relation between 
the numbers of cells labelled with GFAP, F4/80 or IL-6, plasma total-choles-
terol and body weight gain. Statistical analysis was performed using Statistica 
PC software (v.6.0; StatSoft). Values are expressed as mean value ± SEM or as 
percentage of the mean value of the control group ± SEM (n=5 mice/group).
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in vitro-models with human  
neuroblastoma sh-sy5y cells
Paper I: Selective processing of APP by 24S-OHC
The association between cholesterol and AD is, as previously described, an 
established connection with disturbed cholesterol homeostasis and hyper-
cholesterolemia as important risk factors. But the question has been raised as 
to whether the cholesterol in the plasma affects the brain? Plasma cholesterol 
is under normal physiological circumstances not able to cross the BBB, and 
essentially all cholesterol in the CNS is synthesized in situ. It has been demon-
strated that cholesterol homeostasis in the CNS is maintained by the enzyme 
CYP46A1 with a slow conversion of brain cholesterol into 24S-OHC, which 
constitutes the major pathway for excretion of excess cholesterol across the 
BBB. Clinical studies have further demonstrated that the level of 24S-OHC is 
decreased, whereas 27-OH is increased in the brain of AD patients [Heverin et 
al., 2004; Björkhem et al., 2006]. Intriguing and of major significance for paper 
I is the finding that 27-OHC has a net flux from the circulation into the CNS, 
but under normal conditions are found at low levels in the brain due to an ac-
tive elimination process [Heverin et al., 2005; Meaney et al., 2007]. 
Thus, in paper I we aimed to investigate the function of brain cholesterol 
in the pathogenesis of AD, using a human neuroblastoma cell line and the 
oxysterols 24S-OHC and 27-OHC, as well as cells transfected with variants of 
CYP46. Although the response was less marked than in the study by Brown et 
al., we were able to confirm and expand on the former investigation [Brown 
et al., 2004]. We demonstrated that stimulation with 24S-OHC increased the 
α-secretase cleavage and decreased the β-secretase cleavage of APP. We sug-
gest that 24S-OHC exercise a selective preference towards non-amyloidogenic 
pathway through a mechanism different from 27-OHC. 
The decreased response exerted by 24S-OHC on the APP processing, ob-
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served when 24S-OHC and 27-OHC were combined in the cell culture, is 
an important observation as the latter oxysterol represents a possible linkage 
with plasma cholesterol. The possibility must be considered that 27-OHC are 
capable of replacing the more active 24S-OHC and thus reduce the effects of 
24S-OHC on the APP cleavage. 
The α-/β-secretase activity ratio was calculated in order to compare the dif-
ferential effects and was found to be increased after exposure to 24S-OHC, as 
well as in cells transfected with either human (CYP46A1) or murine (CYP46a1) 
cholesterol 24-hydroxylase. We suggest that the α-/β-secretase activity ratio 
could be a convenient method for screening alterations in the APP processing 
pathway in response to different pharmacological treatments.  
In conclusion, we have in paper I demonstrated that 24S-OHC favours the 
non-amyloidogenic APP processing, with subsequently increased extra- and 
intracellular levels of sAPPα and total sAPP. The selective influence on APP 
processing by 24S-OHC and the decreased response observed with 27-OHC, 
provides new insight in how cholesterol affects the AD pathology. Together 
with the findings that the levels of 24S-OHC and 27-OHC are altered in the 
brain of AD patients, and that 27-OHC have a flux into the brain, the described 
observations in paper I may support the hypothesis that 27-OHC could be 
a part of a yet undefined link between plasma cholesterol levels and AD 
[Björkhem et al., 2006].
Paper II: Selective processing of APP and decreased 
apoptosis by rosuvastatin during Aβ exposure
The previously described connection between cholesterol and AD has been 
interpreted as having a potential for cholesterol-lowering compounds, such 
as statins, which could, in turn, have a beneficial effect on AD. This has so far 
yielded inconsistent results in clinical studies. Though, it should be noted that 
different statins may exert slightly different actions. Even though statins per se 
have been associated with a decreased prevalence of AD, we find that the lipo-
philic statins have been reported to cause apoptosis in a variety of cells [Negre-
Aminou et al., 1997; Kubota et al., 2004], whereas to our knowledge no such 
effects have been reported for the statins that belong to the hydrophilic group.
Thus, in paper II we aimed to examine the preventive potential of pre-treat-
ing human neuroblastoma SH-SY5Y cells with hydrophilic rosuvastatin prior 
exposure to aggregates of Aβ1-42 oligomers. Furtermore, we aimed to analyse 
the effects of the cholesterol-lowering therapy on α-secretase activity demon-
strated to be effectively selected by 24S-OHC in paper I, and caspase-3 activity, 
central regulator and early physiological marker of apoptotic cell death [Nico-
tera et al., 1999; Riedl and Shi, 2004]. It has been hypothesized that Aβ peptides 
could function as extracellular signal molecules for caspase-3 activation in AD 
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[Takuma et al., 2004], supported by the findings of an up-regulated caspase-3 
activity in the medial temporal lobe of subjects with early AD [Gastard et al., 
2003]. 
With our results we have established that rosuvastatin therapy decreases cas-
pase-3 activity and increases α-secretase activity in human neuroblastoma SH-
SY5Y, cells without affecting cell viability. These results have been confirmed by 
independent in vitro and in vivo studies [Kilic et al., 2005; Xiu et al., 2006]. We 
can also report a significant reduction of caspase-3 activity, and an increase of 
α-secretase activity, in cells treated with rosuvastatin prior to exposure to toxic 
amyloid aggregates. The response to rosuvastatin was significantly attenuated 
by mevalonate, which suggests that the cholesterol synthesis were restored. We 
suggest that rosuvastatin exerts its effects through an inhibition of the isopren-
oid pathway and regulation of prenylation of important small GTPase signal-
ling molecules. We further suggest that the connection between statins and AD 
could be a link with the lipid rafts, as they have a high cholesterol-associated 
regulatory function on apoptosis and APP processing. 
Additionally, our results suggest that treatment with rosuvastatin alone not 
have an effect on cell viability as measured by the MTT assay, while it was 
clearly demonstrated by the staining with PI that rosuvastatin may decrease the 
detrimental effects induced by exposure to toxic amyloid aggregates. However, 
the percentage of viable cells, as measured by the MTT assay, did not differ 
when exposed to Aβ1-42 alone, compared with rosuvastatin treatment prior 
exposure to Aβ1-42.  We hypothesized that the observed discrepancy could be 
explained by two closely related factors; (i) the MTT assay gives a measure of 
the metabolic activity in the culture and can not identify the amount of surviv-
ing cells per se, and (ii) the possibility must be considered that surviving cells 
exhibit a down-regulated stress response with decreased metabolic activity as a 
reaction to the Aβ exposure [Magrané et al., 2005]. 
In conclusion, we have in paper II reported two mechanisms clearly associ-
ated with the pathogenesis of AD and significantly modulated by rosuvastatin 
therapy in vitro. The connection between the increased α-secretase activity and 
decreased caspase-3 activity, in cells treated with rosuvastatin prior to expo-
sure to aggregated Aβ1-42 oligomers, is an important finding, and may serve 
as a promising target for research on prevention treatment in AD and related 
neurodegenerative diseases.
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in vivo-models with  
wt and apoe-/- mice
Paper III: Rosuvastatin therapy has  
an effect on gliosis and lifestyle risk factors 
The connection between cholesterol and AD has been described previously, and 
in paper III we aimed to go further with the results from paper I–II and exam-
ine the association between dietary cholesterol and AD in vivo. A large number 
of clinical studies have shown consistent results in their claim that dietary re-
striction may have the possibility to suppress brain aging and neurodegenera-
tive disorders such as AD. The association between AD and ApoE deficiencies 
have been suggested to be most critical during the early and middle stages of 
the disease [Dupuy et al., 2001], which further suggests that any therapy that 
will have effect on the disease progression must take place before this stage. 
Lack of ApoE has been found to dramatically reduce Aβ deposition [Bales et 
al., 1997], and it has been suggested that an age-related BBB leakage associated 
with ApoE deficiency could be one of the mechanisms that link ApoE ε4 with 
cholesterol [Hafezi-Moghadam et al., 2007]. In support of the detrimental ef-
fects of ApoE deficiencies it has previously been reported that ApoE-/- mice 
provided with a western type high cholesterol (HC) diet have increased gliosis, 
tau hyperphosphorylation and elevated levels of inflammatory mediators such 
as IL-6 [Crisby et al., 2004; Rahman et al., 2005.b; Rahman et al., 2005.a].
Thus, in paper III we analyzed whether the increased gliosis, as monitored by 
GFAP and previously demonstrated in WT and ApoE-/- mice provided with a 
HC diet, could be decreased by rosuvastatin therapy, and how this would affect 
lifestyle risk factors such as body weight gain and plasma lipoprotein levels.
We found that high levels of dietary cholesterol induced gliosis in WT and 
ApoE-/- mice in support of previous studies, with an increased body weight 
gain and elevated levels of plasma total cholesterol (TC). Using lipid profiles, 
we found the increased TC levels in the WT mice to be caused by increased 
Figure 6. Body weight gain in WT and ApoE-/- mice after 6 weeks (A-B), 12 weeks 
(C-D) and 18 weeks (E-F) respectively. The mice were provided with high levels of 
dietary cholesterol (WTHC, ApoEHC), or diet with rosuvastatin therapy (WTHCRS, 
ApoEHCRS). Mice on normal diet were used as control (WTND, ApoEND). Body 
weight gain was significantly increased by the high-cholesterol diet, and significantly 
decreased with the rosuvastatin therapy, in WT and ApoE-/- mice after 6 and 12 
weeks. However, the significance was found to decrease between 6 to 12 weeks in 
ApoE-/- mice, whereas it increased in WT mice. The response on body weight gain 
was after 18 weeks found to be insignificant in ApoE-/- mice, whereas it remained 
significant in WT mice. n=5 mice/group; *=p<0.005; **=p<0.001; ***=p<0.0001; 
n.s=non significant.
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levels of HDL and LDL, whereas only LDL were increased in ApoE-/- mice. 
Treatment with rosuvastatin significantly decreased the observed gliosis in WT 
and ApoE-/- mice. Furthermore, we demonstrated that the therapy had a sig-
nificant effect on lifestyle risk factors in WT mice, with decreased body weight 
gain, as well as decreased plasma TC and LDL levels.
However, despite the positive effects observed on gliosis in ApoE-/- mice, we 
found the therapy to have an insignificant effect on the measured life style risk 
factors. We suggest that the observed response are associated with the notion 
that ApoE-deficiency, per se, may have a negative effect on various metabolic 
pathways, whereas the response on gliosis could be attributed to the modula-
tion of signalling pathways involving isoprenoids, as well a reduction of overall 
atherosclerosis [Crisby et al., 2002; Grosser et al., 2004]
In Figure 6 we present some hereto unpublished data from the study, which 
clearly illustrates the association between rosuvastatin and ApoE-deficieny, as 
demonstrated by body weight gain after 6, 12 and 18 weeks on high levels of 
dietary cholesterol, with or without, rosuvastatin therapy. Accordingly, the de-
clining response to the therapy was primarily observed in the ApoE-/- mice, 
with a correlation to plasma TC levels after 18 weeks of HC diet and rosuvas-
tatin therapy.
In conclusion, paper III is the first study to report that rosuvastatin may pre-
vent gliosis in the brain of WT and ApoE-/- mice and affect lifestyle risk factors 
in WT mice provided with a HC diet. Clarification of the specific mechanisms 
involved and the responses observed, is a challenge for further research, but 
unpublished data suggests that treatment with rosuvastatin is most effective 
before midlife, with a clearly age- and ApoE -associated declining response to 
the cholesterol-lowering therapy.
Paper IV: Microglial activity and plasma  
IL-6 levels decreased by rosuvastatin therapy
We have in paper III demonstrated the detrimental effects of a western type 
high cholesterol (HC) diet on gliosis and lifestyle risk factors, and the beneficial 
effects exerted by rosuvastatin therapy. We extended these findings in paper IV 
towards the effects of dietary cholesterol and cholesterol-lowering therapy on 
inflammation and inflammatory mediators. 
The occurrence of an inflammation, and the subsequently occurring pro-
inflammatory cytokines, has been lively debated whether they have beneficial 
or detrimental functions in AD. Available facts clearly demonstrate that neu-
roinflammation is not an AD-specific event; nevertheless, AD is characterized 
by a chronic state of inflammation. In addition and as previously described, the 
Rotterdam study has demonstrated that plasma levels of inflammatory pro-
teins such as IL-6 are increased before the clinical onset of AD. Other studies 
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have demonstrated elevated levels of IL-6 in the diffuse plaques formed at an 
early stage of the pathology. Treatment with rosuvastatin has been reported to 
induce isoprenoid depletion, with an indirect effect on microglial activation 
and inflammation, as the isoprenoids play a significant role in the activation 
of IL-6 mediated inflammation [Heinrich et al., 1998; Khwaja et al., 2000]. It 
has also been suggested that it is possible to inhibit the secretion of IL-6 and 
reduce the cell viability of human microglia cells, by treating them with statins 
[Lindberg et al., 2005]. The consequences of a HC diet on inflammation has 
been demonstrated, with an increased microglia load and elevated levels of IL-
6 in the brain of WT and ApoE-/- mice [Rahman et al., 2005.b].
Thus, in paper IV our aim was to examine whether rosuvastatin therapy 
could prevent the increased microglial load and decrease the levels of IL-6 in 
the brain and plasma of WT and ApoE-/- mice provided with a HC diet. We 
found that a HC diet provided for 18 weeks increased the microglial activity in 
the brain of WT and ApoE-/- mice, in support of previous studies. Treatment 
with rosuvastatin demonstrated a clear and significant decrease in microglial 
activity in WT and ApoE-/- mice provided with a HC diet. 
We could also report that despite the increased number of activated micro-
glial cells, there was no increase in IL-6 positive cells observed in the brains of 
WT or ApoE-/- mice on a HC diet. However, even though the levels of IL-6 
in the brain remained largely unaffected were the plasma IL-6 levels found to 
be significantly increased in WT and ApoE-/- mice provided with a HC diet. 
Treatment with rosuvastatin resulted in a large 45% reduction of plasma IL-6 
levels in WT mice on a HC diet; although, the reduction never reached signifi-
cance due to individual variations among the WT mice given dietary choles-
terol without therapy. 
The general response on the dietary cholesterol was found to be significantly 
weaker in the ApoE-/- mice, and we suggest that the observed results in paper 
IV are linked with the findings reported for the ApoE-deficient mice in paper 
III. We further hypothesize that statin therapy of its own accord is insufficient 
to regulate the transcription factors involved in IL-6 mediated inflammation. 
In conclusion, we have in paper IV clearly demonstrated that statin treat-
ment decrease microglial activity in WT and ApoE-/- mice on a HC diet 
provided for 18 weeks. The same therapy was however unable to significantly 
affect the diet-induced chronic inflammatory state; an inflammation possibly 
triggered by a defective regulation of cytokine production and related tran-
scription factors [Libermann and Baltimore, 1990]. With these observations 
we support the growing body of evidence that indicates the importance of 
dietary cholesterol in AD, and how statins may have a beneficial influence in 
the prevention of AD.

47Concluding Remarks  
and Future Perspectives
Current research suggests that the decisions we make early in life could have 
a profound effect on the manner in which our cognitive abilities and selfhood 
are preserved in old age. The research this thesis is built on has focused on the 
implications of cholesterol and cholesterol-lowering therapies in Alzheimer’s 
disease, but with these basic features we have touched on more than one aspect 
of the AD pathology. A major concern is the fact that many of the pathological 
hallmarks in AD, are not AD-specific events as such, but occur in a number of 
different neurological disorders. In addition, with the exception that we still 
have to discover what effects current trends on health, life style and diet will 
have on dementia and prevalence of AD, it has been suggested by demographic 
studies that the prevalence will increase rapidly in the next 50 years [Wancata 
et al., 2003]. Research on AD has primarily focused on means to reduce the 
symptoms, but a new model has been proposed, with the aim to go beyond 
the clinical symptoms; the model postulates that a latent expression of specific 
genes, triggered at the developmental stage by environmental agents, intrinsic 
mechanisms, or dietary factors, could disturb gene regulation in a long-term 
fashion with the pathological results revealed significantly later in life [Lahiri 
et al., 2007].
Factors with a previously described age-associated connection with AD are 
midlife plasma total cholesterol (TC) levels, 24S-OHC levels and inflammation; 
the latter manifested by gliosis and microglial activation, as well as increased 
levels of pro-inflammatory cytokines. A possible connection between plasma 
TC levels and AD has been described in the flux of 27-OHC over the BBB, 
with an inhibitory influence on the selective non-amyloidogenic APP process-
ing induced by 24S-OHC (paper I). This connection has potential for further 
research, aimed towards a deeper understanding of the actual mechanisms 
involved and how to modulate them. We have in this thesis demonstrated that 
dietary cholesterol have detrimental effects on inflammation and a number of 
classic life style risk factors, such as body weight gain and LDL levels (paper III–
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IV). Treatment with rosuvastatin has demonstrated neuroprotective properties 
in vitro (paper II), whereas cholesterol-lowering therapy with rosuvastatin in 
vivo have been able to reduce gliosis, microglial load, plasma IL-6 levels and 
improve the status of the lifestyle risk factors in an age- and ApoE-associated 
manner (paper III–IV). Unpublished data, presented in this thesis, supports 
the hypothesis of an early life-preventive factor in AD, which is suggested to 
be most effective before midlife (paper III). Taken together, it is evident that 
cholesterol-lowering therapies with rosuvastatin may have beneficial effects 
on AD, but when combined with ApoE-deficiencies, the therapies may lose 
their effects after a certain stage in the disease progression. These observa-
tions could hypothetically explain some of the discrepancies found in clinical 
studies, and is supported by the suggestion that the beneficial effects of statins 
are influenced by plasma cholesterol levels, ApoE genotype and the severity of 
dementia [Sparks et al., 2006].
Preventative treatment using caloric restriction (CR) can result in a sub-
stantial longevity benefit if it is initiated during midlife, and delay the onset of 
cognitive dysfunction [Kaerberlein et al., 2006]. Although, with the notion that 
our metabolism changes with age, and that ApoE-deficiencies may have a nega-
tive effect on our metabolism, it is suggested that diet alone may not be a clini-
cally useful treatment in elderly people. As an alternative, the combined effect 
of dietary precautions and cholesterol-lowering therapy may have the potential 
to become an important preventive strategy in AD, with the aim to circumvent 
the inflammatory changes due to hypercholesterolemia, and decrease the im-
pact of lifestyle risk factors. 
Clinical research on health care and nursing practise have already resulted 
in better possibilities to improve quality of life for AD patients, but further re-
search into the health economics of dementia, and early preventive treatments, 
are highly relevant. In addition, larger long-term trials are needed to study the 
effects of rosuvastatins on cognitive functions and how it interacts with current 
therapies using acetylcholinesterase inhibitors, as well as any potential interfer-
ence with the absorption of nutrients. 
In conclusion, this thesis has clearly demonstrated the detrimental effects 
induced by high levels of dietary cholesterol on a selection of Alzheimer’s dis-
ease-associated factors, and that a cholesterol-lowering therapy using rosuvas-
tatin may have a beneficial influence in the prevention of AD. Furthermore, the 
thesis discusses the observation of an age- and ApoE-associated response on 
the therapy. The latter is an important remark, which indicates that rosuvastatin 
may be an efficient therapy up to a certain point in the progression of the dis-
ease, after which the effects decline. These results offer a hypothetical explana-
tion, at least in part, for the discrepancies observed in clinical trials on statins. 
In addition, further evidence for a potential connection between plasma cho-
lesterol and AD has been presented, with a novel function of 24(S)-OHC in the 
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healthy brain found to be decreased by the presence of 27-OHC. The findings 
by Small et al. suggest that it may be possible to prevent early memory deficien-
cies through a combination of relatively simple precautions [Small et al., 2006]. 
An alternative strategy is proposed in which it is hypothesized that lifestyle 
precautions taken in early midlife, in combination with rosuvastatin therapy, 
could be an effective lifestyle-preventive strategy in persons with high risk for 
developing AD. An effective strategy that may have far-going consequences 
with preserved cognitive functions in high age, improved quality of life for 
patients and their families, and decreased cost of dementia care for the society. 
We need a re-examination of current concepts and practices among clinicians, 
researchers and patients, and more work on questions of dementia, selfhood, 
and early prevention therapy, to which the combined efforts presented in this 
thesis may prove to be a valuable contribution.
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alzheimers sjukdom
Alzheimers sjukdom (Alzheimer’s disease; AD) diagnostiserades för första 
gången år 1906 av den tyska läkaren Alois Alzheimer. Patienten var en med-
elålders kvinna vid namn Auguste D som 51 år ålder hade börjat få allvarliga 
symptom på demens och en gradvis försämring av kognitiva funktioner. 
Kognitiva funktioner innefattar högre hjärnfunktioner som tän-
kande, perception, uppmärksamhet, uppfattningsförmåga, minne 
och språk. Begreppet kan härledas ur det latinska ordet cognoscere, 
som betyder att lära.
Auguste D var mycket glömsk, oförmögen att ta hand om sig själv, stundtals 
orolig och misstänksam även mot sin man, men samtidigt medveten om sitt 
behov av andras hjälp. Vid obduktionen fann Alois Alzheimer en rad patologis-
ka (sjukliga) förändringar i hjärnan. Dessa förändringar utgör idag några av de 
kriterier som används för att diagnostisera sjukdomen och består framförallt 
av små, rundade ärrbildningar (neuritiska plack; amyloid plaques) uppbyggda 
av giftiga ansamlingar av protein amyloid-beta (Aβ), störningar av nervcellens 
inre organisation med långa fibrer (neurofibrillär degeneration; neurofibrillary 
tangles) och förlusten av signalvägarna mellan nervcellerna [Bild 7]. Föränd-
ringarna sker i början mycket selektivt, och leder till att nervcellerna förtvinar 
i områden som framförallt har med minne och språk att göra. Så småningom 
sker emellertid en generell degeneration av hela hjärnan. Men sjukdomen är 
komplicerad, och dessa kriterier är i sig själv inte tillräckligt för att kunna ställa 
en diagnos, utan den måste även kunna stödjas av kliniska symptom och en 
klinisk diagnos.
 Idag har omkring 160 000 personer i Sverige en demenssjukdom, varav 
cirka 60% utgörs av AD. Över hela världen var antalet patienter beräknat 
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till ca 30 miljoner människor år 2003, och bara i Sverige drabbas ytterligare 
20–25 000 av någon form av demens varje år. De flesta som drabbats av Alz-
heimer bor hemma under de tidiga stadierna av sjukdomen och vårdas av sina 
anhöriga. Vården av demenssjuka i Sverige beräknas kosta drygt 30 miljarder 
kronor per år, men de anhörigas insatser är mycket svåra att uppskatta i eko-
nomiska termer och av stor betydelse för samhället. 
Alzheimers sjukdom förekommer i två olika varianter, som emellertid inte 
skiljer sig åt vad beträffar symptom eller behandling. Ärftlig (familial) Alzhei-
mers sjukdom (FAD) drabbar ca 10–15% av alla patienter, medan resterande 
85–90% drabbas av den sporadiska formen av Alzheimers sjukdom (SAD). 
FAD har som namnet antyder en stark ärftlig koppling och kan i vissa fall vara 
så aggressiv att den drabbar samtliga vuxna inom en familj. Bland dessa ärftliga 
kopplingar har man funnit ett antal mutationer i generna APP, PS1 och PS2, 
som alla har en stor betydelse för uppkomsten av de förändringar i hjärnan 
som definierar Alzheimers sjukdom.
De flesta fall av Alzheimers sjukdom förekommer sporadisk, utan någon 
tydlig genetisk orsak. Man anser därför att SAD orsakas av den kombinerade 
effekten av flera olika riskfaktorer, där yttre och inre faktorer tillsammans är av 
avgörande betydelse. 
Figure 7. Normal hjärna med frisk vävnad, jämfört med vävnaden från en hjärna 
som drabbats av Alzheimers sjukdom; Döende nervceller, neurofibrillary tangles och 
amyloid (neuritic) plaques.
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Det finns en signifikant ökad risk för ärftlig AD, endast om det inom 
en och samma familj har funnits minst två generationer i direkt 
släktled (t.ex. mormor och mamma, eller föräldrar och syskon med 
samma föräldrar), som drabbats före 65 års ålder och diagnostise-
rats med AD bortom allt tvivel.
Den viktigaste av dessa riskfaktorer är en medfödd genetisk brist i lipoprote-
intransportören apolipoprotein E (ApoE), där isoform ApoE ε4 ökar risken att 
drabbas av sporadisk AD med 300%. Andra riskfaktorer är hög ålder; ökade 
kolesterolnivåer i medelåldern; diabetes; övervikt; högt blodtryck; låg formell 
utbildning; klinisk depression; stroke; stress; Downs syndrom och otillräcklig 
(kontinuerlig) träning av hjärnan. Andra riskfaktorer med en lindrigare kopp-
ling till Alzheimers sjukdom är rökning, höga mängder av alkohol och narko-
tiska preparat. Betydelsefullt är också att kvinnor av okänd anledning drabbas 
i något högre utsträckning än män.
Koppling mellan Alzheimers sjukdom och ålder är viktig. Sjukdomen kan 
uppträda tidigt, speciellt vid den ärftliga formen av AD, då den kan uppträda 
redan vid 28 års ålder, men vanligast är den efter 65 år. Skulle man undersöka 
alla människor över 65 år kommer ca 10% att vara drabbade av någon form av 
AD. Undersöker man enbart gruppen mellan 65 och 74 år kommer man att 
upptäcka att antalet drabbade är ca 5%, vilket ska jämföras med ca 50% bland 
dem som är äldre än 85 år. 
Med undantag för att vi inte vet hur trenderna inom hälsa och träning 
kommer att påverka riskerna för AD, så har forskarna varnat för att den 
ökande medelåldern i världen kan medföra att antalet personer som drabbas 
av demenssjukdomar i framtiden kommer att öka lavinartat. Smärre minnes-
problem och en sämre förståelse av komplicerade sammanhang är en naturlig 
del av vårt åldrande, men hälften av alla svenskar tror att även demens är en 
naturlig del av vårt åldrande och att det drabbar alla som blir äldre. Det här 
är en helt felaktig uppfattning! Demens orsakas av sjukdomar eller skador på 
hjärnan, och de förändringar som sker vid demens, sker utöver de förändringar 
som är en naturlig del av vårt åldrande.
Demens är ett begrepp som kan härledas ur de latinska orden de- 
och mens, som tillsammans betyder frånvarande sinne.
De första tecknen på Alzheimers sjukdom kan ofta vara ganska svåra att 
upptäcka. Förutom mindre minnesproblem förekommer svårigheter att hitta 
ord, uttrycka sig och att förstå komplicerade sammanhang. Utmärkande är 
att symtomen kommer successivt. Det kan därför vara svårt att kartlägga när 
problemen egentligen började. Många symtom återfinns, i varierande grad, hos 
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alla personer med demenssjukdom, men alla personer drabbas olika och sjuk-
domen fortskrider olika snabbt hos olika personer. Sjukdomen påverkas också 
av andra sjukdomar och ökad ålder. 
Några vanliga symptom på tidig Alzheimers sjukdom är problem med 
tidsuppfattningen, svårigheter att hitta i omgivningen, att läsa, skriva, räkna 
och klara av praktiska saker. En del får problem med varseblivningen och har 
svårt att känna igen det de ser och det blir svårare att resonera med dem. En 
del personer får också svåra känslomässiga störningar som påverkar humöret 
och beteendet. 
Vid Alzheimers sjukdom dör nervcellerna i hjärnan onormalt fort. Av de 
områden av hjärnan som brukar drabbas är hippocampus nödvändigt för hjär-
nas minnesfunktioner, och tinning- och hjässloberna har funktioner för vårt 
språk [Bild 8]. Varför nervcellerna dör är fortfarande inte helt klarlagt, men 
en förklaring till många symptom är den uttalade bristen på signalsubstansen 
acetylkolin, som har en viktig funktion vid uppgifter som kräver minne och/
eller uppmärksamhet, och även reglerar hjärnans blodflöde. Detta ledde tidigt 
till en rad behandlingsförsök som påverkade nivåerna av acetylkolin i hjärnan. 
Figure 8. Tvärtsnitt av en normal hjärna med frisk vävnad, jämfört med vävnaden 
från en hjärna som drabbats av Alzheimers sjukdom; Bredare sulcus (dalgångar), 
mindre gyrus (berg) och större ventriklar (hålrum). Två viktiga areor i Alzheimers 
sjukdom är språk och minne, med en tydlig illustration av den utbredda degenera-
tionen.
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Behandlingar med acetylkolinesterasinhibitorer har visat sig vara en effektiv 
metod när det gäller att minska de symptomatiska besvären, men det finns 
fortfarande ingen behandling som har effekt på den huvudsakliga sjukdoms-
processen. Alzheimers sjukdom är en kronisk sjukdom med dödlig utgång.
Alzheimers sjukdom och andra demenssjukdomar är de största enskilda 
anledningarna till att vi idag har stora vårdbehov i hemmen och på våra insti-
tutioner. Som en direkt konsekvens av sjukdomen anser man ofta att patienter 
med demens och allvarliga kognitiva problem inte längre är där, med deras 
personlighet och kanske även deras människovärdighet, kraftigt ifrågasatt. 
Patienter med långt framskriden sjukdom kräver onekligen stor omsorg, men 
lika sant är det att sjukdomen medför en enorm psykologisk belastning på 
patienternas familjer och närstående. Vid långt framskriden sjukdom upplevs 
situationen ibland svårare av familjerna än av patienterna, och Alzheimers 
sjukdom kan därför med rätta kallas de anhörigas sjukdom. 
kolesterol och  
kolesterolsänkande terapi
Denna avhandlig har huvudsakligen fokuserat på hur höga kolesterolvärden 
i maten påverkar olika faktorer som är associerade med Alzheimers sjukdom, 
och hur vi kan påverka dessa faktorer med hjälp av en kolesterolsänkande te-
rapi med rosuvastatin. Rosuvastatin är en effektiv hämmare av kolesterolsynte-
sen, och har visat sig vara en effektiv behandling av förhöjda kolesterolvärden 
och inflammationer i CNS.
Vi har först och främst demonstrerat att en kolesterolrik diet har en effekt på 
hjärnan och det centrala nervsystemet (CNS), trots att det runt hjärnan finns 
en skyddande barriär som kallas blod-hjärn barriären (blood-brain barrier; 
BBB). Denna BBB har till uppgift att bevara hjärnas integritet och kontrollerar 
vilka ämnen i kroppen som påverkar nervcellerna i hjärnan. Under normala 
omständigheter finns ca 25% av allt kolesterol i hjärnan, trots att den bara 
upptar ca 2% av kroppsvolymen. Detta till synes märkliga förhållande har sin 
förklaring i det faktum att kolesterolet har en central roll i cellernas funktion 
och bl.a. är nödvändigt för att nervcellerna ska kunna kommunicera. Men i och 
med att kolesterolet inte kan passera BBB måste i princip allt kolesterol i hjär-
nan tillverkas i hjärnan, med en mycket liten andel från blodet och maten. Hur 
kan då en kolesterolrik diet påverka hjärnan och CNS? Det finns flera olika 
teorier om detta, men en hypotetisk koppling som vi har haft möjlighet att un-
dersöka i artikel I, är konverteringen mellan kolesterol, 27-hydroxykolesterol 
(27-OHC) och 24(S)-hydroxykolesterol (24S-OHC). Denna konvertering gör 
det lättare för kolesterolet att passera BBB. Tidigare studier har också visat att 
27-OHC kan röra sig över BBB, från blodet och in i hjärnan. Väl inne i hjärnan 
representerar 27-OHC en direkt (hypotetisk) länk mellan kolesterolnivåerna 
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i blodet och kolesterolet i hjärnan. Vi har i artikel I visat att       27-OHC har ett 
negativt inflyttande på de processer som representerar icke-AD, med signifi-       
kans för sjukdomsförloppet i Alzheimers sjukdom. 
I artikel II visade vi att nervceller reagerar positivt på en behandling med 
rosuvastatin, vilket skulle kunna öka deras möjligheter att skydda sig mot den 
celldöd som framkallas av Aβ. Denna behandling har även visat sig vara effek-
tiv som kolesterolsänkande terapi. I artikel III och IV visade vi hur kolesterolet 
i dieten påverkade kroppen negativt med en ökad inflammation i hjärnan, 
och att en kolesterolsänkande terapi med rosuvastatin kan ha en tänkbar 
skyddande inverkan. Men våra rön tyder på att effekterna av rosuvastatin till 
viss del sker via mekanismer som inte är associerade med kolesterolnivåerna 
i kroppen, och att de dessutom kan associeras med både ålder och defekter i 
lipoproteintransportören ApoE, vilket hypotetiskt skulle kunna förklara en del 
motsägelsefulla resultat som har rapporterats i kliniska studier på statiner.
Vi har också visat att en kolesterolrik diet har en direkt effekt på olika 
faktorer som berör vår livsstils, det vill säga faktorer som representerar hur 
vi lever och som är möjliga att påverka med relativt enkla medel. Genom att 
ändra livsstil ökar vi våra möjligheter att behålla våra kognitiva funktioner och 
vår livskvalitet även i hög ålder. En kalorisnål diet (caloric restriction; CR) har 
t ex visat sig kunna förlänga vår livslängd om man börjar vid medelåldern, 
och även vara en effektiv preventiv åtgärd mot kognitiva försämringar. Men 
med tanke på att vår metabolism förändras när vi blir äldre och att bristande 
funktioner i ApoE inte bara är associerade med AD, utan också med negativa 
effekter på vår metabolism, kanske CR i sig inte är en lämplig behandling mot 
Alzheimers sjukdom.
De åtgärder som rekommenderas är enkla och logiska råd som ge-
nerellt omfattar ett aktivt och sunt liv; fysisk aktivitet; fritidsaktivi-
teter; utbildning och minnesträning; strukturerad tillvaro; närings-
rik mat och dryck; minskning av högt blodtryck; social samvaro och 
normala kolesterolvärden.
Denna avhandling har visat på några av de skadliga effekter som höga nivåer 
av en kolesterolrik diet orsakar i hjärnan, och de möjligheter till förebyggande 
behandlingar som finns med kolesterolsänkande terapier med rosuvastatin. 
Men rönen tyder även på att en rosuvastatin terapi sannolikt inte är en till-
räckligt effektiv insats mot Alzheimers sjukdom, då effekterna av behandlingen 
avtar i direkt association med ålder och defekter i ApoE. Vi föreslår därför en 
alternativ strategi där man kombinerar rosuvastatin tillsammans med åtgärder 
som påverkar vår livsstil och håller vår hjärna aktiv (se ovan). Om det initieras 
i tidig medelålder hos personer med risk att utveckla Alzheimers sjukdom, 
skulle det kunna vara en effektiv livsstilsförebyggande strategi med bevarade 
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kognitiva funktioner, bevarad livskvalitet i hög ålder och minskade kostnader 
för samhället. Utvecklingen av alternativa vårdformer har visat att det går att 
förbättra tillvaron och livskvaliteten för patienterna och deras familjer. Men vi 
behöver även en omvärdering av nuvarande idéer och av vårt förhållningssätt 
till patienter med demenssjukdomar, och mer forskning på frågor om demens 
och tidiga preventions terapier, till vilket den presenterade avhandlingen för-
hoppningsvis ska vara ett värdefullt bidrag.
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Time glides by with constant movement, not unlike a stream. 
For neither can a stream stay its course, nor can the fleeting hour.
Assiduo labuntur tempora motu, non secus ad flumen. 
Neque enim consistere flumen, nec levis hora potest. 
— Ovid, Metamorphoses XV
